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l Foreword
We are proud to present the 25th General Report of Activities of the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), which provides an overview of the 
agency’s key achievements in 2019.
It was a year in which we released 32 scientific and corporate publications, in addition 
to 30 Country Drug Reports presenting the situation in the EU Member States, Norway 
and Turkey. Our analyses were accessed, via our website, by 1.7 million visitors and we 
contributed to almost 300 scientific and institutional drug events during the year. More than 
500 drug professionals were trained at the capacity-building activities carried out by the 
EMCDDA, many of which were held in cooperation with our partners.
Two EMCDDA flagship publications, namely the European Drug Report 2019 and the third 
edition of the EU Drug Markets Report (which was produced jointly with Europol), were 
launched in Brussels by Dimitris Avramopoulos, the European Commissioner for Migration, 
Home Affairs and Citizenship. These reports contributed new evidence on the dynamic drug 
phenomenon and the increasingly innovative EU drug market, which was estimated to be 
worth at least EUR 30 billion a year.
At a time when public health concerns are growing, we are proud to announce that, 
collaboratively with some key partners, our agency effectively acted on three key priorities: 
tackling the problem of drug-related deaths, supporting effective harm reduction 
interventions and engaging with drug prevention professionals. A wealth of resources were 
released, including the highly praised European Prevention Curriculum handbook, which 
we hope will enhance the efforts of many specialists working in this important field in the 
years to come.
This was also the first year of operation under the new legislative framework of the EU Early 
Warning System (EWS) on new psychoactive substances (NPS). In close collaboration 
with our partners, which include the Reitox EWS network in the Member States, Norway 
and Turkey, and five EU agencies, we ensured the efficient implementation of the EWS. In 
addition, eight risk communications were issued and the EWS was notified for the first time 
of 53 NPS in 2019, bringing the total number of substances under monitoring to around 
780.
Providing timely information to the EU drug policy debate was a transversal priority of the 
agency and much of our efforts were put into analysing and reporting on the developments 
in the evolving cannabis market; these culminated in a new report, several topic overviews, 
regular cannabis policy news items and a briefing note, all of which were provided to our 
key stakeholders, namely EU and national policymakers in the drugs field.
Throughout the year, working in partnership was vital for the EMCDDA. Core to our activities 
were our established data providers in the EU Member States, Norway and Turkey, which 
form the invaluable Reitox network of national focal points. While, in 2019, the network 
held its 60th meeting at our premises in Lisbon, the year also saw important concerns 
being raised regarding the sustainability of the network in the context of the challenging 
financial perspective faced by the EMCDDA. A key commitment was made by the agency 
and its main network to together identify the actions needed to mitigate the impacts of any 
resource limitations and to ensure their viability and the very existence of the EU drug-
monitoring system overall.
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Another key development in our work with partners was the inception of two important EU-
funded technical cooperation projects, one for six of the candidate and potential candidate 
countries and one for 15 of the European Neighbourhood Policy countries.
Working in partnership also made possible the organisation, in Lisbon, of the Third 
European Conference on Addictive Behaviours and Dependencies, which is also known as 
‘Lisbon Addictions’. The conference also had a record number of international participants 
in 2019, namely 1 300. The EMCDDA was one of the co-organisers of this event and 
contributed over 60 presentations and e-posters.
Throughout the year, we were honoured to receive recognition for our sustained efforts, 
which came from practitioners working in the field, our partners and drug policymakers.
In this regard, the report published by the European Commission in May on the fourth 
external evaluation of the EMCDDA, which it carried out in 2018, confirmed that over the 
past six years the agency had continued to be widely recognised as a true hub of scientific 
excellence in Europe and internationally. We will nonetheless continue to improve our 
services in the years to come; information in this respect will be provided in the follow-up 
action plan that was adopted by the EMCDDA Management Board in December.
Finally, but importantly, we are pleased to announce that, in 2019, the EMCDDA achieved 
its highest performance ever, both operationally and financially. This was only possible 
thanks to the hard work and commitment of our staff.
We would also like to express our gratitude to the members of the Management Board for 
their ongoing support and guidance. Special thanks go to our Scientific Committee, which 
reached the end of its mandate in 2019. We know that we may count on the new Scientific 
Committee to advise us in the years to come.
Our final appreciation goes to all of our networks and partners, which enriched our work 
and enhanced our results in 2019.
Laura d’Arrigo 
Chair of the EMCDDA Management Board 
Alexis Goosdeel 
Director of the EMCDDA
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 List of acronyms and abbreviations
AASC Assembly of Agency Staff Committees
ABAC electronic management and accounting system
CELAC Community of Latin American and Caribbean States
CEPOL EU Agency for Law Enforcement Training
CICAD Inter-American Drug Abuse Control Commission
CND UN Commission on Narcotic Drugs
COPOLAD Cooperation Programme between Latin America and the European Union on Drugs 
Policies
COSI Standing Committee on Operational Cooperation on Internal Security
CSC Council Security Committee
DG HOME Directorate-General for Migration and Home Affairs
DG NEAR Directorate-General for Neighbourhood and Enlargement Negotiations
DG SANTE Directorate-General for Health and Food Safety
DGPNSD Delegación del Gobierno para el Plan Nacional sobre Drogas
DPO data protection officer
ECDC European Centre for Disease Prevention and Control
ECDD Expert Committee on Drug Dependence
ECHA European Chemicals Agency
EDMR European Drug Markets Report
EDND European Database on New Drugs
EDPS European Data Protection Supervisor
EDR European Drug Report
EEAS EU External Action Service
EFSA European Food Safety Authority
EFUS European Forum for Urban Security
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform Against Criminal Threats
EMSA European Maritime Safety Agency
ENI European Neighbourhood Instrument
ENISA EU Agency for Cybersecurity
ENP European Neighbourhood Policy
EPSO European Personnel Selection Office
ERISSP European Reporting Instrument on Sites related to Synthetic Production
ESCAPE European Syringe Collection and Analysis Project Enterprise
ESPAD European School Survey Project on Alcohol and Other Drugs
EU4MD EU4Monitoring Drugs
EU-ACT EU Action Against Drugs and Organised Crime
EU-ANSA EU Agencies Network on Scientific Advice
EUPC European Prevention Curriculum
Euro-DEN Plus European Drug Emergencies Network
EWS Early Warning System
FRA EU Agency for Fundamental Rights
GAT ‘GAT IN Mouraria’ (Grupo de Ativistas em Tratamentos)
HCV hepatitis C virus
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HDG Horizontal Drugs Group
HFP head of national focal point
IAS Internal Audit Service
ICF Internal Control Framework
ICT information and communication technology
IPA Instrument for Pre-Accession Assistance
ISCTE-IUL ISCTE — University Institute of Lisbon
ISSUP International Society of Substance Use Prevention and Treatment Professionals
JHA Justice and Home Affairs
KPI key performance indicator
LIBE Civil Liberties, Justice and Home Affairs
NFP national focal point
NGO non-governmental organisation
NPS new psychoactive substances
OAP operational action plan
OSI open-source information
PD programming document
PM2 Project Management Squared
PWID people who inject drugs
SCORE Sewage Analysis CORe group Europe
SICAD Serviço de Intervenção em Comportamentos Aditivos e Dependências
SOCTA Serious Organised Crime Threat Assessment
UN United Nations
UNAIDS Joint UN Programme on HIV/AIDS
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
Xchange online registry of evidence-based prevention programmes
I
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Mission statement
Independent, science-based information is a vital resource 
to help Europe understand the nature of its drug problems 
and better respond to them. It was based on this premise, 
and in the face of an escalating drugs phenomenon, that the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) was established in 1993. Inaugurated in Lisbon in 
1995, it is one of the EU’s decentralised agencies.
Building on the EMCDDA’s Founding Regulation (Regulation 
(EC) No 1920/2006) as amended (Regulation (EU) 2017/2101 
as regards information exchange on, and an early warning 
system and risk assessment procedure for, new psychoactive 
substances (NPS)), the EMCDDA Strategy 2025 defines the 
agency’s current mission and vision statements.
l Mission
The EMCDDA exists to support evidence-based decisions and 
actions at EU and national levels by providing factual, objective, 
reliable and comparable information concerning drugs and 
drug addiction, and their consequences. The EMCDDA’s 
mission is therefore grounded in the consensus that sound 
information is a prerequisite for developing effective policies in 
the drugs area.
l Vision
The EMCDDA’s vision is a healthier and a more secure Europe, 
achieved through better informed drug policy and action.
To do this effectively, the agency must constantly strive to 
respond to the needs of its primary customers, who can be 
defined as:
  EU institutions;
  national decision-makers/policymakers;
  professionals working in the drugs field.
Beyond meeting the information needs of primary customers, 
to address its mandate the EMCDDA also needs to engage 
with other stakeholders, including academic institutions and 
researchers; the general public, civil society and those affected 
by drug problems; and international organisations and third 
countries.
l Values
The EMCDDA is committed to the EU and its values. Beyond 
these, the agency has identified its own set of core values to 
inform all aspects of its work, inspire staff in their professional 
performance, inform future organisational policies and guide 
the agency’s interactions with stakeholders and partners.
The EMCDDA’s four core values are:
  scientific excellence;
  integrity and impartiality;
  customer focus and service orientation;
  efficiency and sustainability.
1
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This report presents the implementation of the activities of 
the EMCDDA’s work programme for 2019, the first year of the 
multiannual programming document (PD) 2019-21.
The report mirrors the work programme for 2019, which, in line 
with the EMCDDA Strategy 2025, presents the activities of the 
EMCDDA within the three main areas of work: health, security 
and business drivers.
While the EMCDDA has clear objectives and priorities in each 
area, it is important to note that the multifaceted nature of 
the drugs problem means that these areas are interlinked and 
complementary. Therefore, for the purpose of this executive 
summary, a section that includes transversal work is presented 
first.
l Transversal work: health and security
In 2019, the agency continued to produce timely and high-
quality information, together with strategic and situational 
analyses and threat assessments, to inform policy and practice. 
In this regard, the agency’s most tangible outputs are its 
publications, some of which are produced in cooperation with 
partners. In 2019, 32 scientific and corporate publications, 
in addition to 30 Country Drug Reports, were released by 
the EMCDDA. The agency also authored or co-authored 22 
scientific articles and book chapters, which were published in 
prestigious journals and publications, enhancing the agency’s 
scientific reputation.
Furthermore, over 1.7 million visitors accessed the EMCDDA 
website in 2019 (i.e. 4 700 visits per day), an increase of 26 % 
compared with 2018 and of 60 % compared with 2017.
One of the most downloaded resources was the European 
Drug Report (EDR) of 2019, the EMCDDA’s yearly flagship 
publication. The report was launched on 6 June at the 
European Commission in Brussels by Dimitris Avramopoulos, 
the European Commissioner for Migration, Home Affairs and 
Citizenship, and by Alexis Goosdeel, the EMCDDA Director. 
Available in print and as a PDF in 24 languages, the EDR 2019 
was accompanied by the Statistical Bulletin 2019, which 
contained the European dataset underpinning the analysis, 
and 30 Country Drug Reports, which presented summaries of 
national drug phenomena. National launches of the EDR and 
the Country Drug Reports were organised in 12 EU Member 
States.
The EMCDDA continued to disseminate its information and 
analysis through the year by attending and contributing to 
almost 300 scientific and institutional events (see Annex 5 for 
a full list of events attended by EMCDDA staff).
This information dissemination was complemented by training 
and capacity-building activities, which allowed the agency to 
transfer its knowledge to more than 500 professionals working 
in the drugs field, including law enforcement officers and 
policymakers both in the EU and beyond.
Specific highlights from the EMCDDA’s work within the three 
main areas — health, security and business drivers — are 
presented below and details can be found in the later sections 
of the report and in the annexes.
l Health area
Through its Strategy 2025, the EMCDDA is committed to 
contributing to a healthier Europe by addressing important 
drug-related public health concerns. In this regard, the 
EMCDDA’s public health priorities in 2019 were as follows: to 
contribute to the reduction of drug-related deaths, to promote 
hepatitis C testing and treatment among people who inject 
drugs (PWID) and to promote the implementation of evidence-
based prevention interventions.
Reducing drug-related deaths is a major public health 
challenge. To support the EU efforts in this area, the EMCDDA 
launched five new resources focusing on drug overdoses in 
Europe and the interventions in place to prevent them.
CHAPTER 1
Executive summary
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The year 2019 was the second year of implementation of the 
EMCDDA harm reduction initiative, which aims to develop 
high-quality materials for capacity-building and training 
activities for those working in the field. Work in this area 
included the launch of a new set of resources aiming to 
enhance hepatitis C virus (HCV) care among PWID and the 
development, in collaboration with EU partners and experts, 
of an ‘elimination barometer’ for viral hepatitis, with the aim 
of helping countries to assess their progress in eliminating 
hepatitis C and B among PWID.
The EMCDDA also substantially supported the implementation 
of evidence-based interventions to prevent drug use. This 
included the publication of a new European Prevention 
Curriculum (EUPC) handbook, a manual that is designed to 
train professionals who are involved in shaping prevention 
decisions, opinions and policies in Europe in the science-
based prevention of substance use. This new resource was 
subsequently used at the first EUPC ‘training for trainers’ 
course — a joint initiative of the EMCDDA and the EU-funded 
project ‘ASAP training for quality in prevention’, which took 
place at the agency’s headquarters in Lisbon.
This was also the first year of operation of the new legislative 
framework on NPS, which strengthened the EU Early Warning 
System (EWS) on NPS. Therefore, while an important part of 
the agency’s resources in this area were dedicated to adapting 
the relevant guidelines, procedures, processes and tools to 
the new legal framework, the EMCDDA continued to ensure 
the robust implementation of the EWS, together with its EU 
partners, which now include the Reitox EWS network and 
five EU agencies, in addition to the EMCDDA. The EU EWS 
was formally notified for the first time of 53 NPS during the 
year, bringing the total number of NPS currently monitored 
to around 780. Furthermore, eight risk communications were 
issued to the EU EWS network.
In the policy area, much of the agency’s efforts went on 
following up on the developments in the evolving cannabis 
market, in order to promptly inform the EU policy debate. To 
that end, a new report and several topic overviews were 
released, and regular cannabis policy news items were issued 
on relevant European and international developments in 
this field. Furthermore, a briefing note on the World Health 
Organization Expert Committee on Drug Dependence (WHO-
ECDD) recommendations on cannabis and related substances 
was provided to the European Commission upon request. The 
EMCDDA Reitox Academy entitled ‘Understanding cannabis 
policies — changes and challenges’ was also organised 
in Lisbon, with the aim of improving the understanding of 
different cannabis policy models and their implementation, as 
well as of methods to assess the impact of changing cannabis 
policies.
An ongoing priority in the policy area was to contribute to 
the implementation of the EU action plan on drugs 2017-20 
and to support the European Commission, as required, in the 
evaluation of the EU drugs strategy 2013-20. In this regard, the 
EMCDDA provided the European Commission and the external 
evaluators of the EU drugs strategy with an information-rich 
briefing note entitled The EMCDDA’s contribution to the final 
evaluation of the EU drugs strategy 2013-20 and of the EU 
action plan on drugs 2017-20.
The information and analysis provided by the EMCDDA in 
the health area were supported by the ongoing, underlying 
monitoring work that was carried out by the agency 
throughout the year. The core monitoring activity (based on 
the five EMCDDA key epidemiological indicators) was further 
strengthened, with a significant contribution from the Reitox 
network of national focal points (NFPs), the agency’s main 
data providers in the Member States, while new data sources 
continued to be investigated.
These ‘leading edge’ indicators provide useful, timely and 
complementary data that offer valuable insights into drug 
use in Europe. To that end, the EMCDDA enhanced its 
collaboration with innovative initiatives, including the Sewage 
Analysis CORe group Europe (SCORE) on wastewater analysis, 
the European Web Survey on Drugs (providing data on drug 
consumption in different populations of drug users in 16 
European countries), the European Drug Emergencies Network 
(Euro-DEN Plus, an organisation that monitors emergency 
data on acute drug-related harm that are provided by selected 
hospitals in 18 European countries), the European Syringe 
Collection and Analysis Project Enterprise (ESCAPE) and 
the Trans-European Drug Information Project (TEDI). Data 
collected from the EMCDDA’s collaboration with these 
initiatives fed many of the EMCDDA’s analyses that were 
produced and published during the year.
l Security area
A large amount of effort in this area in 2019 went into the 
launch of the third joint EMCDDA-Europol EU Drug Markets 
Report (EDMR) and its supporting digital information package. 
This publication provides a strategic and action-oriented 
analysis that combines data from the EMCDDA’s drug-
monitoring system with Europol’s operational intelligence 
on organised crime. The 2019 EDMR was accompanied 
by a comprehensive range of resources. These included 
a booklet presenting EDMR highlights for policy and practice 
and 12 papers/reports addressing knowledge gaps identified 
since the previous (2016) edition of the report, such as 
darknet markets and the supply of drugs, using open-source 
General Report of Activities 2019 CHAPTER 1 I Executive summary
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information (OSI) to improve the European drug-monitoring 
system, and methamphetamine in Europe.
This new flagship report was launched at a press conference 
in Brussels on 26 November by Commissioner Dimitris 
Avramopoulos and the directors of the two EU agencies. The 
press conference was followed by a dynamic EMCDDA-
Europol ‘meet the authors’ event, which offered around 90 
stakeholders the opportunity to explore the report ‘hands-on’ 
with representatives of the two agencies.
Important progress was made by the agency in understanding 
the nature and consequences of drug-related crime. During 
the year, the EMCDDA exchanged information with EU drug-
related crime expert groups, and new analyses were published 
(as part of the EDMR 2019 package) on essential topics such 
as drug-related homicides, organised crime groups involved in 
drug supply, and terrorism and drugs in Europe.
In the policy area, the EMCDDA provided technical input 
and advice to its key partners, in particular the European 
Commission, on issues such as drug distribution via the 
internet/darknet and cooperation with third countries. The 
agency also provided input on the European Commission’s 
proposal for an indicator to be used to evaluate funding 
decisions made in the Internal Security Fund 2021-27, which 
is part of the next multiannual financial framework (2021-27) 
of the EU.
Furthermore, the agency continued to contribute to the 
European Multidisciplinary Platform Against Criminal Threats 
(EMPACT) operational action plans (OAPs) of the EU Policy 
Cycle on organised and serious international crime. This 
included the publication, jointly with Europol, of the EDMR 
2019, the provision of input on the drafting of the EMPACT 
OAPs for 2020 on NPS/synthetic drugs and on cannabis, 
cocaine and heroin, and the organisation of training activities 
for 169 law enforcement professionals with the EU Agency for 
Law Enforcement Training (CEPOL).
To support the comprehensive analytical effort in the security 
area, work continued in 2019 on improving the quality and 
availability of core supply data, in close collaboration with 
the Reitox NFPs and with our EU partner Europol. In terms of 
new sources of data and innovative monitoring approaches, 
the EMCDDA further developed its capacity for OSI and 
darknet monitoring, which have been gaining importance in 
understanding the rapidly evolving and increasingly ‘tech savvy’ 
drug market.
l Business drivers
l Institutional developments
Further to the fourth external evaluation of the EMCDDA, 
which was carried out by the European Commission in 
2018, the Commission published a report in May positively 
evaluating the work of the agency. The report confirms that, 
over the period 2013-18, the agency continued to be widely 
recognised as a true hub of scientific excellence in Europe 
and internationally, providing factual, objective, reliable and 
comparable data at the European level on drugs and drug 
addiction and their consequences.
Commissioner Avramopoulos stated: ‘The EU drugs agency 
has become a genuine European hub of excellence on the 
increasingly transnational challenge of drug use and abuse, 
helping us make more informed and more effective policies at 
both national and EU level to counter the threats and harms 
associated with it.’
Subsequently, a follow-up action plan was adopted by the 
EMCDDA Management Board in December. An internal 
discussion and strategic-thinking exercise started in 2019 
with a view to analysing the focus for the work of the EMCDDA 
in the future, so that it best responds to the evolving needs 
of its stakeholders within the context of possible resource 
constraints.
l  Communication and service delivery to meet evolving EMCDDA customer needs
At the core of the EMCDDA’s endeavour to bring maximum 
value to its key customers is to understand, and possibly 
even anticipate, their evolving needs. To that end, a ‘customer 
needs project’ was initiated by the EMCDDA in 2018, with the 
overall objective of improving how the agency engages with 
its primary customer groups and ensuring that their feedback 
informs decision-making and service development. The project 
took an important step in 2019 by defining and applying 
a set of qualitative and quantitative techniques that allow 
the agency to tune into the ‘customer voice’. This is essential 
for embedding and sustaining customer focus and service 
orientation at the EMCDDA.
Further activities were carried out to enhance engagement 
with the agency’s audience, in particular via the online 
communication channels. As a result, the upwards trend in 
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the number of social media followers continued in 2019, with 
an increase in the number of followers for all of the channels 
(i.e. an increase of between 7 % for Facebook and 25 % for 
Instagram). Engagement with the media also significantly 
increased in 2019. The EMCDDA serviced 378 requests from 
journalists during the year, 40 % more than in 2018.
l Working in partnership
In fulfilling its tasks, the agency relies on a large number of 
partners and, in particular, the Reitox network of NFPs, which 
plays a critical role in sustaining the EU core monitoring 
system. An important anniversary in the life of the network 
was celebrated in 2019, namely the 60th meeting of the 
Reitox heads of NFPs (HFPs) in Lisbon in May. During the 
year, the Reitox development framework, which defines 
the main priorities for the network in line with the EMCDDA 
Strategy 2025, continued to be implemented by the EMCDDA 
and the NFPs. One of the issues focused on in 2019 was the 
sustainability of the network in the context of the challenging 
financial perspective faced by the EMCDDA. In this regard, 
the HFPs and the agency engaged in a dialogue to together 
identify any possible measures to mitigate the impact of 
resource limitations and to ensure the viability of the network, 
of the EMCDDA and of the EU drug-monitoring system in 
general.
In performing its work and achieving its objectives, the 
EMCDDA also relies on its other EU and international partners. 
At the institutional level, two new working arrangements were 
concluded, namely with the European Chemicals Agency 
(ECHA) and the European Food Safety Authority (EFSA), with 
a view to implementing the new NPS legislation.
In terms of cooperation with third countries and international 
organisations and support for EU-funded projects, work was 
guided by the EMCDDA International Cooperation Framework, 
which was adopted by the Management Board in December 
2017.
In this area, the agency continued to cooperate with 
enlargement countries and to implement the Instrument for 
Pre-Accession Assistance (IPA) technical cooperation projects. 
In this regard, 2019 saw the completion of the IPA 6 project 
(which started in 2017) and the start, on 1 July, of the IPA 7 
project. Entitled ‘Stepwise integration of the IPA beneficiaries 
in the activities of the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and the Reitox network’, 
this new project, with a total budget of EUR 1 million and 
a duration of 36 months, aims to enhance the capacity of the 
EU and the six IPA beneficiaries to detect, analyse and report 
on emerging drug-related health and security threats.
At the institutional level, a new working arrangement between 
the EMCDDA and Albania was concluded on 13 March in 
Vienna. The agreement was signed by EMCDDA Director 
Alexis Goosdeel and by the Albanian Deputy Ministers of the 
Interior and of Health and Social Protection, Besfort Lamallari 
and Mira Rakacolli, in the presence of Commissioner Dimitris 
Avramopoulos.
On 1 January, a technical cooperation project was also set up 
with European Neighbourhood Policy (ENP) partner countries, 
financed by the European Neighbourhood Instrument (ENI). 
The project, entitled ‘EU4Monitoring Drugs’ (EU4MD), has 
a total budget of EUR 3 million and is planned to run until the 
end of 2021, with the objective of supporting national and 
regional readiness in the ENP area (for 15 potential partner 
countries) to identify and respond to drug-related health and 
security threats. Technical assessment visits were conducted 
in eight countries, followed by the setting up of a capacity-
building plan for the lifetime of the project. More than 14 
capacity-building activities were reported for 87 professionals.
l Scientific capacity
In December, the EMCDDA Management Board appointed 
15 high-level scientists to serve on the agency’s Scientific 
Committee for the period 2020-22. The selection followed 
a call for expressions of interest in the Official Journal of the 
European Union, which yielded 78 eligible applications. In 
addition, the Management Board also adopted a list of experts 
to be used by the EMCDDA Director to extend the EMCDDA 
Scientific Committee for the purposes of the assessment of 
the risks posed by NPS.
World experts reviewed the future of addictions at the 
Third European Conference on Addictive Behaviours and 
Dependencies, which took place in Lisbon in October. A record 
1 300 participants — researchers, practitioners and policy 
experts from all over the world — attended the event. The 
focus of the 2019 conference was ‘Future of addictions: 
new frontiers for policy, practice and science’ and 850 
presentations were distributed over 150 sessions and 264 
e-posters were showcased. Besides being a co-organiser of 
the conference, the EMCDDA played an active role, delivering 
over 60 presentations and e-posters, which covered topics 
including the challenges of monitoring new drugs, drug-
checking technology, HCV testing and care, and cannabis 
policies.
l Corporate performance
During the year, the agency performed well, both operationally 
and financially. This was confirmed by the high level of 
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implementation of the 2019 work programme, which was 
measured by key performance indicator (KPI) 7, ‘Work 
programme delivery’ (see Annex 4). This KPI was achieved 
for the level 1 outputs/results (i.e. 100 % achieved, in line 
with the target) and was overachieved for the level 2 outputs/
results (i.e. 92 % achieved – against the target of 80 %) and 
the level 3 outputs/results (i.e. 77 % – against the target of 
50 %). The agency’s performance was also demonstrated 
by the outstanding results achieved in terms of budget 
execution — in 2019, the agency reached the maximum level 
of performance, with 100 % of commitment appropriations 
executed.
2
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l Main area 1: Health
l Core monitoring
The annual core data-collection and management activities 
are key tasks set up in the EMCDDA’s Founding Regulation 
(recast). These are implemented every year in close 
collaboration with the agency’s main data providers, namely 
the Reitox network of NFPs in the EU Member States, Norway 
and Turkey.
Central to this core monitoring activity are the five key 
epidemiological indicators:
  GPS describes the prevalence and patterns of drug use 
among the general population;
  PDU focuses on the prevalence and patterns of high-risk 
drug use;
  TDI is the treatment demand indicator;
  DRD describes drug-related deaths and mortality among 
drug users;
  DRID describes drug-related infectious disease.
Monitoring prevalence and patterns of drug use plays a vital 
role in our understanding of the drug situation in Europe. In 
2019, the EMCDDA launched two new topic pages on its 
website, one on the prevalence and patterns of drug use and 
one on general population surveys.
In June, the EMCDDA also published its ‘Latest update on 
drug-related infectious diseases in Europe’, providing an 
overview of the most recent infectious disease surveillance 
data, outbreak investigations, and prevention and control 
measures among PWID in Europe.
Analytical work was further developed to inform key EMCDDA 
outputs, in particular the EDR package.
Despite the limited resources available, in 2019, the EMCDDA 
continued to support the European School Survey Project on 
Alcohol and Other Drugs (ESPAD) — this included support 
for ESPAD’s coordination and data-collection activities, the 
development of ESPAD’s online presence and the preparation 
of the ESPAD report (for publication in 2020).
CHAPTER 2
Monitoring and reporting on the drugs 
problem
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Support for EU priority third countries continued under the 
framework of the technical assistance projects IPA 6, IPA 7 and 
EU4MD (for details, see ‘Business driver 2: partnership’ under 
‘Main area 3: Business drivers’).
The EMCDDA scaled up work in the area of drugs and prisons. 
One example of this work was the European Questionnaire 
on Drug Use among People living in prison (EQDP) project 
to collect harmonised data on drug use in the prison setting, 
which, in 2019, had nine participating countries.
Work in the area of drugs and prisons will culminate with 
the launch of an in-depth overview of the topic in 2020, 
incorporating an overview of drug demand, drug supply and 
best practices in the prison context.
Drug overdoses: in the spotlight
FIguRE 1. Drug overdoses: quote by the EMCDDA 
Director
’Overdose deaths are 
preventable. We know 
from research that many 
of those who die have 
been struggling and 
living on the margins 
of society for years. 
We know that those 
who overdose once are 
at a very high risk of 
overdosing again. And 
we know that effective 
preventive and response 
measures exist that 
would allow us to avoid 
many deaths.’
Through its Strategy 2025, the EMCDDA is committed 
to contributing to a healthier Europe. Reducing drug-
related deaths is a major public health challenge. In 
August, ahead of International Overdose Awareness Day, 
the EMCDDA launched three new resources looking at 
drug overdoses in Europe and the interventions in place 
to prevent them:
  Prevention of drug-related deaths, providing the 
latest overview on this issue and the risk factors 
involved;
  the first overview of Take-home naloxone (THN) 
programmes in Europe, describing how these 
programmes developed and became more common 
over the past decade;
  Frequently asked questions (FAQs): drug overdose 
deaths in Europe, raising questions such as 
the following: Where have drug-related deaths 
increased most over the last 10 years? Are women 
and men affected equally? What are the current 
concerns in Europe?
Earlier in the year, the EMCDDA published its latest 
update on Drug-related deaths and mortality in Europe, 
shedding light on important public health challenges 
faced by European policymakers and stakeholders, 
with regard to monitoring, prevention, risk assessment, 
harm reduction and drug treatment. An analysis of 
post-mortem toxicology practices in drug-related death 
cases in Europe was published in April, discussing the 
effect of these practices on the monitoring of drug-
related deaths.
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European Drug Report 2019: in the spotlight
FIguRE 2. Launch of the EDR 2019: quote by EU 
Commissioner Dimitris Avramopoulos
FIguRE 3. Launch of the EDR 2019: quote by the 
EMCDDA Director
Record cocaine seizures, challenges associated 
with heroin and new synthetic opioids, and the latest 
developments in the cannabis market are among the 
issues focused on in the EDR 2019, released on 6 June.
The report was launched at the European Commission 
in Brussels by Dimitris Avramopoulos, the European 
Commissioner for Migration, Home Affairs and 
Citizenship, and by Alexis Goosdeel, the EMCDDA 
Director.
Available in print and as a PDF in 24 languages, the EDR 
2019 was accompanied by the Statistical Bulletin 2019, 
which contained the European dataset underpinning 
the analysis, and by 30 Country Drug Reports, which 
presented summaries of national drug phenomena.
National launches of the EDR and the Country Drug 
Reports were organised in 12 Member States, with eight 
national launches taking place with the participation of 
EMCDDA staff.
In addition, a video, two news releases in 24 languages 
(i.e. a taster news release and a highlights news 
release), a special edition of the newsletter Drugnet 
Europe and a promotional brochure were produced by 
the agency to mark the launch of the EDR.
In parallel, the EMCDDA started its work to improve and 
revise the future EDR package. For this purpose, various 
audiences were invited to participate in a short survey 
(available in English, French, German, Italian, Polish, 
Portuguese and Spanish) in order to better understand 
their needs and shape the future EDR accordingly.
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l  Responding to new psychoactive substances: EU Early Warning System and risk assessment
This was the first year of operation of the new legislative 
framework on NPS (1), which brought about an important 
change in the implementation of the EU EWS on new drugs. 
This new legal instrument retains the three-step approach 
to responding to NPS — early warning, risk assessment and 
control measures — while significantly strengthening existing 
processes by streamlining and accelerating data-collection 
and assessment procedures.
Therefore, while a significant number of the agency’s 
resources in this area were dedicated to adapting the relevant 
guidelines, procedures, processes and tools to the new legal 
framework, and ensuring a smooth transition between the 
two legal instruments, the EMCDDA continued to ensure 
the robust implementation of the EU EWS, together with its 
partners in the Member States (the Reitox network of the EWS 
correspondents), Europol and the European Medicines Agency 
(EMA), as well as its new partners, namely the European 
Centre for Disease Prevention and Control (ECDC), ECHA and 
EFSA.
Key outputs of the EWS included risk communications issued 
to the EWS network, namely rapid formal notifications of the 
first detection in Europe of new substances, public health 
alerts on NPS, the exchange of forensic and toxicological 
analytical data, and outputs related to the implementation of 
the new NPS legislation.
FIguRE 4. New psychoactive substances monitoring 
in 2019
(1) From 23 November 2018, Council Decision 2005/387/JHA was replaced 
with Regulation (Eu) 2017/2101 of the European Parliament and of the 
Council of 15 November 2017 amending Regulation (EC) No 1920/2006 as 
regards information exchange on, and an early warning system and risk as-
sessment procedure for, new psychoactive substances.
As shown in Figure 4, the EMCDDA’s main activities in this 
area were as follows:
  case reports on 53 NPS detected for the first time in the 
EU were received, processed and analysed — literature 
available for each of those substances was assessed, and 
available information was appraised prior to issuing the 53 
formal notifications to the EU EWS network;
  around 780 NPS were monitored by the EU EWS, as of the 
end of 2019;
  417 case reports and reporting forms on NPS detected 
in the EU were received, processed, analysed and, as 
relevant, uploaded into the European Database on New 
Drugs (EDND);
  eight risk communications, including alerts, briefings and 
advisories were issued to the EU EWS network.
Some of the EMCDDA’s central activities continued to 
be network management and the provision of technical 
assistance on a daily basis to the members of the Reitox EWS 
network. This was particularly important in 2019, as much of 
the effort of the agency was dedicated to providing support to 
ensure a smooth transition to the implementation of the new 
NPS legislation. This included extensive consultation with the 
EWS network on the guidelines, procedures, processes and 
tools that had to be progressively adapted and put in place for 
the effective operation of the EU EWS.
A key outcome of this process was the EMCDDA operating 
guidelines for the European Union Early Warning System 
on new psychoactive substances, addressing measures 
introduced by the new legislation. The guidelines, which 
replace those published in 2007, are accompanied by 
guidance notes and detail the rationale, steps, procedures, 
roles and responsibilities for operating the system.
The agency visited some EWS NFPs (such as the Irish and the 
Finnish EWS NFPs) and provided training to national EWS 
experts under the framework of the Reitox Academies (see 
‘Business driver 2: partnership’ under ‘Main area 3: Business 
drivers’). The 19th annual meeting of the Reitox EWS network 
took place on 18 and 19 June. All of the presentations given 
at this meeting and the minutes of the proceedings were 
published in the EDND.
This was also an important year for revamping the EDND. 
Following the extensive developmental work that had 
been carried out in several phases, the new database 
(EDND 2) became operational. It provides new and important 
functionalities, such as the management and reporting of 
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event-based information, and so supports more efficient 
implementation of the EU EWS.
The EMCDDA has a leading role in monitoring and responding 
to NPS in the EU. In 2019 the EMCDDA actively participated 
in scientific and technical events, which allowed the agency’s 
knowledge to be disseminated and its experience to be shared 
with other actors in the field (see Annex 5 for a full list of 
events attended by EMCDDA staff).
An important event that took place in 2019 was the Sixth 
International Conference on Novel Psychoactive Substances, 
held on 8 and 9 April in Maastricht, the Netherlands. The event 
was organised by the United Nations Office on Drugs and 
Crime (UNODC), the EMCDDA, the World Anti-Doping Agency, 
the University of Hertfordshire and Maastricht University. The 
EMCDDA created the scientific programme (and financed the 
printing of the hard copies of the programme), gave keynote 
presentations and opened and closed the conference.
The agency also provided technical input and advice to its 
key partners, in particular the European Commission, on 
issues such as fentanils, vaping and e-liquids, and the Opioid 
Initiative Task Force (led by the EMA). Furthermore, the agency 
was actively engaged in the exchange of information with the 
European Commission’s Early Warning and Response System 
on the outbreak of serious lung injury in the United States 
among people who use e-cigarette products.
Reflecting the world-leading expertise and role played by 
the EMCDDA in the NPS area, particularly in relation to early 
warning, the EMCDDA provides information, expertise and 
advice each year to UNODC and the WHO. In particular, the 
EMCDDA sent information on all of the NPS detected by the 
Member States in 2018 to UNODC; furthermore, it contributed 
to reviewing the new UNODC guidelines that examine the 
role of drug analysis laboratories in the EWS. The EMCDDA 
also assisted the WHO-ECDD with data for the prioritisation 
process and for the preparation of critical reviews, which 
informed the discussions held at the 42nd ECDD meeting.
The agency’s work with third countries that are a priority for 
the EU (namely candidate and potential candidate countries) 
continued in 2019 under the framework of the IPA 6 project, 
which ended in July (see ‘Business driver 2: partnership’ under 
‘Main area 3: Business drivers’).
In that regard, Serbia’s national EWS profile was published in 
July. This profile presents the structure, objectives and working 
methods of the Serbian national EWS on NPS. It describes the 
functions of the institutions participating in the EWS and refers 
to data-collection tools.
Furthermore, the recommendations formulated after the 
assessment mission to Montenegro in 2018 were sent in the 
format of a roadmap to the Montenegrin Ministry of Health 
and Ministry of Interior by both the EMCDDA Director and 
the Director of the Directorate-General for Neighbourhood 
and Enlargement Negotiations (DG NEAR) in April 2019. This 
was followed by a new mission to Montenegro, on 17 and 
18 July, in which the EMCDDA Director and senior agency 
staff participated. The high-level visit aimed to (1) follow 
up on the 2018 assessment report on the establishment of 
a national drug observatory and EWS, namely to understand 
the state of compliance of Montenegro with the series of 
recommendations provided by the EU further to that report, 
and (2) take stock of the state of cooperation between 
Montenegro and the EMCDDA and provide a new incentive 
for such cooperation, namely under the new European 
Commission-funded technical cooperation project IPA 7 (see 
‘Business driver 2: partnership’ under ‘Main area 3: Business 
drivers’).
In addition, the EMCDDA cooperates with other third countries 
in the framework of arrangements concluded under regional 
EU-funded projects, including the Cooperation Programme 
between Latin America, the Caribbean and the European 
Union on Drug Policies (COPOLAD). The EMCDDA participates 
regularly in COPOLAD meetings of the Working Group 1.3 on 
Early Warning Systems. In particular, in 2018-19, the EMCDDA 
contributed to developing new guidelines on establishing EWS 
adapted for the Community of Latin American and Caribbean 
States (CELAC).
l New trends and health threats
To improve the timeliness of reporting, it is crucial that new 
and flexible monitoring tools complement the EMCDDA’s core 
monitoring system. In 2019, the agency further developed and 
strengthened its system for monitoring and understanding 
new and emerging trends in drug use and drug markets.
The EDR 2019 drew on a selection of newer, targeted data 
sources. These ‘leading edge’ indicators provide useful, timely 
and complementary data that offer valuable insights into drug 
use in Europe (see Figure 5).
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FIguRE 5. New indicators to complement existing data 
sources
For example, wastewater analysis provides a snapshot of drug 
volumes consumed at the community level in cities across 
Europe. This is illustrated by new data for 2018, released 
by SCORE and the EMCDDA in March 2019, which point to 
greater geographical diffusion and an overall increase in the 
consumption of all the commonly used classes of stimulant 
drugs.
Other new data sources include the European Web Survey on 
Drugs, which aims to obtain in-depth data on the consumption 
of cannabis, MDMA, cocaine and amphetamines in different 
populations of drug users in 16 European countries. In April, 
EMCDDA experts analysed the use of multinational web 
surveys for comparative analysis, based on the lessons learned 
from a scientific article on the reliability and validity of the 
European Web Survey on Drugs published in the International 
Journal of Drug Policy.
Hospital emergency data on acute drug-related harm can 
increase our understanding of the public health impact 
of the use of drugs in Europe. Drug-related acute toxicity 
presentations in selected hospitals in 18 European countries 
are monitored by Euro-DEN Plus. The findings from the 2019 
analysis illustrate how the drugs responsible for emergency 
presentations can vary across Europe.
In May, the EMCDDA published a new report entitled Drugs in 
syringes from six European cities: results from the ESCAPE 
project 2017, presenting the results of an innovative method 
for gathering information on the substances used by PWID 
(see Figure 6).
Information from drug-checking services was also reviewed in 
the framework of the EDR 2019.
The EMCDDA played an important role in developing the new 
indicators of drug use in Europe. For example, the agency 
helped to increase the number of participants in wastewater 
analysis, run web surveys, collect syringe residues, monitor 
hospital emergencies and harmonise data collection and 
presentation. Moreover, the EMCDDA continued to support 
the expansion of the networks that monitor this information to 
enhance understanding of the drug situation in Europe.
Furthermore, the agency endeavoured to anticipate the 
developments in the EU drug situation through a ‘Futures’ 
exercise (planned to be completed in 2020). The exercise helps 
the agency to maintain a state-of-the-art understanding of 
the extent of drug use, patterns, trends and impacts on public 
health and to identify future reporting needs. In 2019, a series 
of events took place, including a ‘megatrends’ workshop with 
the NFPs as part of the meeting of the HFPs in November 
(see ‘Business driver 2: partnership’ under ‘Main area 3: 
Business drivers’), and sessions on the futures of drugs and 
of addictions at the Lisbon Addictions 2019 conference (see 
‘Business driver 3: scientific capacity’). Finally, within the EU 
Agencies Network on Scientific Advice (EU-ANSA), in 2019, the 
EMCDDA chaired a working group on ‘Futures’, where a draft 
EMCDDA paper on the methodological aspects of the Futures 
exercise was presented at the network meeting in November.
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l Drug interventions
Activities in this area were directed towards professionals 
working in the drugs field, as they are key EMCDDA customers.
Best Practice Portal
Identifying the best practices among, and the factors 
determining the effectiveness of interventions across the EU 
and beyond is a key area of work for the EMCDDA, and the 
main dissemination channel of this information is the Best 
Practice Portal.
In 2019, existing modules were kept updated and new 
modules were added on, among others, the following topics:
  treatment for amphetamine-type stimulants use 
disorders;
  psychosocial interventions to reduce cocaine and 
amphetamine use;
  neurostimulation techniques for the treatment of 
substance use;
  pharmacotherapies for the treatment of cocaine use 
disorders.
In the prevention area, the Best Practice Portal has been 
extended to include the identification of effective programme 
examples. The databases on interventions in nightlife settings 
(the Healthy Nightlife Toolbox) and the online registry of 
evidence-based prevention programmes (Xchange) were 
updated with new entries (see ‘Prevention: in the spotlight’ for 
further details).
FIguRE 6. Drugs in syringes from six European cities: results from the ESCAPE project 2017
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Prevention: in the spotlight
FIguRE 7. Cover of the EUPC handbook
The EMCDDA made substantial progress in achieving 
its goal — outlined in the EMCDDA Strategy 2025 — to 
support interventions to prevent drug use that are based 
on evidence.
Advancing the professionalism of the drug prevention 
workforce in Europe is at the heart of the new EUPC 
handbook, launched in September. The manual is 
designed to train professionals who are involved in 
shaping prevention decisions, opinions and policies in 
Europe in the science-based prevention of substance 
use.
The first EUPC ‘training for trainers’ course took place 
in September in Lisbon; this was a joint initiative of the 
EMCDDA and the EU-funded project ‘ASAP training for 
quality in prevention’. A total of 29 participants from 
11 countries took part in the training, including two 
participants, one from Georgia and one from Lebanon, 
who were funded through the EU4MD project.
Furthermore, the EMCDDA added 16 new programmes 
to Xchange, its online registry of evidence-based 
prevention programmes. The registry, which now
Participants at the ‘training for trainers’ event of 24-26 September at 
the EMCDDA (© EMCDDA).
contains 38 programmes, showcases interventions that 
European evaluation studies have demonstrated as 
having promising outcomes relating to substance use.
A new report presenting substance-use prevention in 
Europe through the lens of a system was also released 
to highlight the wide range of factors that need to be 
addressed to successfully implement programmes and 
policies on substance-use prevention.
The importance of the prevention topic in the context 
of various interventions was stressed by the EMCDDA 
Director. This included a presentation entitled 
‘Prevention and treatment of drug-related deaths in 
Europe’ at the United Nations (UN) Commission on 
Narcotic Drugs (CND) in March, and a speech at the 
opening session of the International Conference on 
Drug Prevention, Treatment and Care — Inspiration and 
Direction, which was organised in Vienna, in July by the 
International Society of Substance Use Prevention and 
Treatment Professionals (ISSUP).
General Report of Activities 2019 CHAPTER 2 I Monitoring and reporting on the drugs problem
24 / 86
Training and capacity building
Another effective means of disseminating best practice is 
through training activities. During the year, several such events 
took place, including Reitox Academies and training initiatives, 
which were held in cooperation with traditional partners such 
as the University Institute of Lisbon (ISCTE-IUL).
The Reitox Academies are the EMCDDA’s main capacity-
building initiative. Eight Reitox Academies were organised in 
2019 for 212 professionals from EU Member States and non-
EU countries (for details, see ‘Business driver 2: partnership’ 
under ‘Main area 3: Business drivers’).
The eighth European Drugs Summer School was jointly 
organised by the EMCDDA and ISCTE-IUL from 24 June 
to 5 July in Lisbon. In total, 43 students of 26 different 
nationalities attended the course. Five participants received 
a bursary offered through the EU4MD project. The event was 
very positively evaluated by both students and lecturers.
Harm reduction
In 2019, the EMCDDA continued to promote good practices in 
harm reduction, including the integration of evidence-based 
practices, interventions and policies into routine healthcare 
and public health settings. The preparation of the second 
edition of the European Responses Guide was ongoing (for 
publication in 2020), while additional information resources 
were developed in important public health areas, including 
hepatitis C in particular (see ‘EMCDDA harm reduction 
initiative: in the spotlight’ for details).
EMCDDA harm reduction initiative: in the spotlight
FIguRE 8. Hepatitis C: new models of care for drug 
services
This was the second year of implementation of the 
EMCDDA harm reduction initiative, which aims to 
develop high-quality materials for capacity-building 
and training activities for those working in the field. 
These materials are developed based on the agency’s 
ongoing monitoring activities in the field of epidemiology 
and responses, as well as on existing evidence-based 
intervention guidance.
In July, the EMCDDA launched a new set of hepatitis 
resources. These included an outline of the EMCDDA 
initiative and the results of pilot tests conducted in the 
first half of 2019. These were complemented by 11 case 
studies from eight European countries, illustrating new 
approaches to enhance the HCV care cascade among 
PWID (comprising findings about the effectiveness, 
sustainability and transferability of these new models of 
care).
Furthermore, a knowledge questionnaire was designed 
and published to refresh the knowledge of and identify 
training needs around hepatitis C among practitioners 
working in drug services.
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l Drug policies
Support for drug policy at the EU level
Throughout the year, the EMCDDA continued to provide 
technical input and advice to drug policymakers at the EU level, 
namely to the European Parliament, the Council of the EU and 
the European Commission, as well as to policymakers in the 
Member States, as they are key EMCDDA customers.
Regarding the European Parliament, ongoing contact was 
maintained; the EMCDDA Director met several Members of 
the European Parliament and he gave presentations at two 
meetings of the Committee for Civil Liberties, Justice and 
Home Affairs (LIBE Committee) of the European Parliament, 
on 19 February and 4 September (see ‘EMCDDA Director: 
main activities’ under ‘Business driver 4: management’). 
Furthermore, a delegation of the LIBE Committee visited the 
EMCDDA on 30 and 31 October with a view to getting a better 
insight into the EMCDDA’s activities and achievements. An 
overview of drug-related policy challenges within Europe was 
provided by the agency, including highlights from the EDR 
2019, the implementation of the EU EWS and updates on 
fentanyl and opioid use in Europe. International developments, 
such as cannabis policies and cannabis for medicinal 
purposes, were also presented by the EMCDDA.
Concerning the Council, the agency provided support to the 
Romanian and the Finnish Presidencies. The agency attended 
regular and ad hoc institutional and technical meetings 
upon invitation, including 10 meetings of the Horizontal 
Drugs Group (HDG) and two meetings of the National Drugs 
Coordinators, the latter having taken place in Bucharest 
(9-10 April) and Helsinki (25 September). The EMCDDA 
also contributed to EU expert dialogues such as EU-CELAC, 
EU-Dublin Group, EU-Brazil, EU-Peru, EU-US, EU-Russia, 
EU-Eastern Partnership and EU-Civil Society Forum on 
Drugs, along with the HDG. More than 20 presentations were 
delivered, including on the EDR 2019 and the EDMR 2019. 
A full list of events attended by EMCDDA staff in 2019 can be 
found in Annex 5.
In terms of collaboration with the European Commission, the 
EMCDDA provided technical support throughout the year. 
This included contributing to the implementation of the EU 
action plan on drugs 2017-20, as well as providing support, 
upon request, to the final evaluation of the EU drugs strategy 
2013-20. The EMCDDA supported the European Commission 
and the external evaluators of the EU drugs strategy with 
an information-rich briefing note entitled The EMCDDA’s 
contribution to the final evaluation of the EU drugs strategy 
2013-20 and of the EU action plan on drugs 2017-20. This 
briefing note provided the available information on the actions 
for which the EMCDDA is a responsible party and on the 
actions for which the agency is a data provider.
Another important document was the briefing note on 
cannabis reclassification to support the development of the 
EU common position on the WHO-ECDD recommendations, 
which was sent to the European Commission in December, 
further to its request. Other contributions were sent on issues 
such as the annual report questionnaire, NPS (see earlier 
section ‘Responding to new psychoactive substances: EU Early 
Warning System and risk assessment’) and drug supply (see 
‘Main area 2: Security’).
Last but not least, the EMCDDA provided input to the European 
institutions, namely to help prepare several sub-committees 
and bilateral security dialogues and to review documents. The 
agency contributed to the security dialogue with Indonesia and 
a dialogue with Colombia, and to the review of the non-papers 
on the accession of Montenegro and Serbia.
Finally, in September, the EMCDDA worked with its 
expert network on drug-related infectious diseases on an 
‘elimination barometer‘ for viral hepatitis, with the aim 
of helping countries to assess their progress towards 
eliminating hepatitis C and B among PWID. This 
barometer was the focus of a new EMCDDA technical 
report published in September entitled Monitoring the 
elimination of viral hepatitis as a public health threat 
among people who inject drugs in Europe.
The use of structured roundtable discussions or 
workshops was the core element recommended by 
the barometer in the diagnostic process. In 2019, the 
EMCDDA piloted this approach in Luxembourg and 
Poland (see panel ‘Feedback from workshop participants’).
Feedback from workshop participants
Gathering all barriers and recommendations 
together and defining specific actions to 
implement these recommendations was very 
useful.
The meeting had high professional level, 
a large dose of practical information, as well 
as many different approaches and solutions to 
identified problems.
I can guide people better, because I know how 
the different services work.
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The CND, the central UN policymaking body in drug-related 
matters, held its 62nd session in Vienna from 14 to 22 March 
(more details on the EMCDDA´s cooperation with UN partners 
can be found in ‘Main area 3: Business drivers: partnership’). 
The EMCDDA supported the EU delegations and EU Member 
States in their efforts towards the adoption of the UN 
Resolutions led by the EU. An EMCDDA delegation attended 
the event to provide technical support to the European 
Commission and the EU Member States, participate in a series 
of side events and make EMCDDA products available at 
a publications stand.
Cannabis: in the spotlight
FIguRE 9. Video on developments in the European 
cannabis market
Cannabis is the most commonly used illicit drug in 
Europe. It is also the drug about which both public 
attitudes and political debate are most polarised. In 
its work in this area throughout 2019, the EMCDDA 
broadened and deepened its overview of evidence and 
current practice to inform debate through, among others, 
the release of topic overviews on the status and recent 
developments related to cannabis policy.
Cannabis products have become increasingly diverse 
in Europe, and close monitoring of their potency and 
potential health effects is essential. A new EMCDDA 
report published in June entitled Developments in the 
European cannabis market highlights greater diversity, 
increasing potency and the need for close monitoring 
of health effects of cannabis products. A video is also 
available presenting the highlights of the report (see 
Figure 9).
In June, the EMCDDA Reitox Academy on 
‘Understanding cannabis policies — changes and 
challenges’ was held in Lisbon, which aimed to improve 
participants’ understanding of different cannabis policy 
models and their implementation, as well as of methods 
to assess the impact of changing cannabis policies 
(see ‘Business driver 2: partnership’ under ‘Main area 3: 
Business drivers’).
In response to growing interest in the topic of the 
medical use of cannabis and cannabinoids, and as more 
European countries develop policies and practice in 
this area, the EMCDDA released French and Spanish 
versions of the report Medical use of cannabis and 
cannabinoids: questions and answers for policymaking 
(see Figure 10).
Furthermore, throughout the year, regular cannabis 
policy news items were released on relevant European 
and international developments in this field.
During the Lisbon Addictions conference, in October, 
an ‘International cannabis toolkit workshop’ took place. 
Funded by the Society for the Study of Addiction, the 
EMCDDA and the Portuguese General Directorate for 
Intervention on Addictive Behaviours and Dependencies 
(Serviço de Intervenção em Comportamentos Aditivos 
e Dependências — SICAD), the workshop aimed 
to address these pressing global issues by bringing 
together the most recent evidence and multidisciplinary 
expertise from addiction scientists, clinicians and 
international agencies such as the EMCDDA.
FIguRE 10. Multilingual versions of the report on 
medical cannabis
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Support for drug policy in the Member States
National policymakers are one of the three key customer 
groups outlined in the EMCDDA Strategy 2025, and several 
activities were carried out by the agency in relation to this 
group in 2019.
At the technical level, the agency provided support to Estonia, 
Cyprus and Portugal in the evaluation of their national drug 
strategies and/or evaluations.
Furthermore, after the successful policy evaluation workshop 
for EU Member States, which was organised by the agency 
for the first time in 2018, a second workshop took place in 
September 2019. The event aimed to build the knowledge 
and expertise of those engaged in commissioning, managing 
and using evaluations of policies and strategies in EU Member 
States. The attendees came from a variety of government 
departments and focal points. Participants were asked to 
complete an anonymous questionnaire, and feedback was very 
positive. The participating countries were Belgium, Czechia 
and Sweden, and these were joined by two representatives 
from Georgia, funded by the EU4MD project (see ‘Business 
driver 2: partnership’ under ‘Main area 3: Business drivers’).
Within the same project, the workshop ‘An introduction to drug 
policy evaluation’ took place on 19 and 20 October. The aim of 
this workshop was to build the knowledge and understanding 
of policy evaluation among people working in the field of drug 
policy in EU4MD partner countries. Representatives from 
six countries took part (Armenia, Belarus, Jordan, Moldova, 
Palestine (2) and Ukraine). The attendees came from a variety 
of government departments and roles.
Presentations were also delivered at national drug policy 
events (see ‘EMCDDA Director: main activities’ under 
‘Business driver 4: management’ and Annex 5 for details). This 
included the national launches of the EDR 2019 — out of the 
12 countries that organised a national launch, eight had an 
EMCDDA staff member present, as follows: Bulgaria, Czechia, 
Cyprus, Poland, Portugal (January 2020), Romania, Slovenia 
and Finland.
Furthermore, seven high-level visits from representatives of 
the EU Member States and Norway took place at the EMCDDA 
in 2019, which provided an excellent opportunity for the 
agency to present its work and updates on the main drug 
policy developments in Europe and internationally.
An important event in 2019 was the visit of His Excellency 
the President of the Portuguese Republic, Marcelo Rebelo de 
Sousa, to the EMCDDA.
(2) This designation shall not be construed as recognition of a State of Palestine 
and is without prejudice to the individual positions of the Member States on 
this issue. Applies to all mentions of Palestine in this document.
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Portuguese President pays first visit to the EMCDDA
The President of Portugal, Marcelo Rebelo de Sousa, 
paid his first visit to the EMCDDA on 10 July for an 
insight into the work of the agency and the latest trends 
and developments in the drug situation in Europe.
During the visit, the President said: ‘We cannot allow 
the positive results of public policies over the last 20 
years to diminish the importance of the drugs issue on 
the political agenda. Nothing is ever definitively won. EU 
Member States must continue to invest in knowledge 
and information to support effective interventions that 
contribute to reducing the social harms of drug use 
and trafficking. This effort must be achieved collectively, 
because only together can EU countries tackle this 
increasingly sophisticated problem.’
President of Portugal, Marcelo Rebelo de Sousa  
(© press office of the President).
EMCDDA staff with the President of Portugal, Marcelo Rebelo de Sousa (© press office of the President).
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Another event that took place in 2019 was the International 
Day Against Drug Abuse and Illicit Trafficking (26 June). The 
EMCDDA marked this occasion with a reception on its premises 
for the Lisbon diplomatic community and its partners from the 
Portuguese authorities. The theme for the UN international day 
in 2019 was ‘Health for justice. Justice for health’.
Other events were organised in the Member States. Two of 
these events, which also marked some of the 2019 highlights 
in working with the Member States, took place in Spain.
The EMCDDA was awarded a Gold Medal of the Order of Merit 
of the Spanish national plan on drugs (Delegación del Gobierno 
para el Plan Nacional sobre Drogas) in recognition of, and 
appreciation for, its work over the past 20 years. The EMCDDA 
Director, Alexis Goosdeel, received the medal on behalf of the 
agency on 9 January from the Spanish Minister for Health, 
Consumer Affairs and Social Welfare, María Luisa Carcedo. The 
EMCDDA was praised for the ‘extraordinary relevance’ of its 
work and its contribution to the adoption of national and EU-
level policies based on evidence and scientific knowledge.
Later in the year (18-19 September), a Reitox Academy on 
‘Communicating with national policymakers’ took place in 
Madrid. The event was organised by the EMCDDA and the 
Spanish NFP, under the auspices of the Ministry of Health, 
Consumer Affairs and Social Welfare. Over 20 participants 
from 14 countries attended the event, which aimed to 
explore the needs of this group, strengthen the role of the 
NFPs in informing policymaking and improve their capacity 
to contribute to the policy debate. The first session drew on 
the insights of two national policymakers: José Manuel Freire 
(health spokesperson of the Spanish Socialist Parliamentary 
Group of the Madrid Regional Assembly) and Alexandre 
Quintanilha (Portuguese socialist Member of Parliament 
and former chair of the expert committee at the origin of the 
Portuguese drug policy).
Finally, the EMCDDA supported innovative national initiatives, 
such as the Final Conference of the Solidify Project. The 
European Forum for Urban Security (EFUS), the City of Lisbon 
and the EMCDDA hosted the Final Conference of the Solidify 
Project on 5 and 6 December in Lisbon. The project, which 
has been run by EFUS since January 2018, focused on the 
implementation and sustainability of drug consumption rooms 
in selected European cities and their impact. The conference 
offered the chance to exchange views on innovative and 
human rights-based local drug policies, the role of drug 
consumption rooms in this endeavour and the political 
challenges around the issue. It also reviewed how fostering 
constructive local multi-agency partnerships in relation to drug 
consumption rooms could form an essential basis for their 
positive impact and for urban security and public tranquillity.
l Main area 2: Security
l  Drug market monitoring and identification of new trends
The drug-related market in Europe is continuously evolving, 
and providing a comprehensive understanding of this market 
requires ongoing effort to improve our core monitoring system, 
in parallel with exploring and using any novel data-collection 
approaches. To that end, work on improving the quality and 
availability of core supply data continued in 2019, in close 
collaboration with our national data providers and with our EU 
partner Europol.
In terms of new sources of data and innovative monitoring 
approaches, the agency further developed its capacity for OSI 
and darknet monitoring, which have been gaining importance 
in developing our understanding of the rapidly evolving and 
increasingly tech savvy drug market.
Furthermore, similar to the work carried out under the health 
pillar, support for EU priority third countries continued under 
the framework of the technical assistance projects IPA 6, 
IPA 7 and EU4MD on security-related issues and with regard 
to supply-related data (for details, see ‘Business driver 2: 
partnership’ under ‘Main area 3: Business drivers’).
In terms of key outputs, a large amount of effort in 2019 went 
into the launch of the third joint EMCDDA-Europol European 
Drug Markets Report (EDMR) and its supporting digital 
information package (see ‘European Drug Markets Report 
2019: in the spotlight’ for details).
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EU Drug Markets Report 2019: in the spotlight
Europeans are spending at least EUR 30 billion on drugs 
each year at the retail level, making the drug market 
a major source of income for organised crime groups in 
the EU. This figure was announced in the 2019 EDMR 
that was released jointly by the EMCDDA and Europol 
(see Figure 11) — the two agencies joined forces 
to provide their third state-of-the art overview of the 
European illicit drug market.
The report was launched at a press conference in 
Brussels on 26 November by Dimitris Avramopoulos, 
European Commissioner for Migration, Home Affairs and 
Citizenship; Alexis Goosdeel, EMCDDA Director; and 
Catherine De Bolle, Europol Executive Director.
The publication offers a strategic and action-oriented 
analysis, combining data from the EMCDDA’s 
drug-monitoring system with Europol’s operational 
intelligence on organised crime.
The report covers trends along the supply chain from 
production and trafficking to distribution and sales.
The 2019 EDMR — available in English in print and as 
a PDF file — is accompanied by a comprehensive range 
of resources, presented on a dedicated event page. 
These include a booklet, presenting EDMR highlights for 
policy and practice, and 12 papers/reports addressing 
the knowledge gaps identified since the 2016 edition, as 
follows:
  six supporting papers:
  Drug precursor developments in the European Union;
  Using open-source information to improve the 
European drug monitoring system;
From left to right: Alexis Goosdeel, EMCDDA Director; Dimitris 
Avramopoulos, European Commissioner for Migration, Home Affairs 
and Citizenship; and Catherine De Bolle, Europol Executive Director.
FIguRE 11. Estimated retail value of the illicit market for 
the main drugs in the EU
  EMCDDA pilot study of drug-related homicide in 
Finland, the Netherlands and Sweden;
  Methamphetamine in Europe: Europol-EMCDDA threat 
assessment;
  Estimating the size of the main illicit retail drug 
markets in Europe: an update;
  Developments in the European cannabis market;
  six EMCDDA-commissioned reports:
  An assessment of the extent of Albanian(-speaking) 
organised crime groups involved in drug supply;
  Analysis of the supply of drugs and new psychoactive 
substances by Europe-based vendors via darknet 
markets in 2017-18;
  Shifting sands — Libya’s changing drug trafficking 
dynamics on the coastal and desert borders;
  Technology-facilitated drug dealing via social media in 
the Nordic countries;
  An analysis of the costs of dismantling and cleaning 
up synthetic drug production sites in Belgium and the 
Netherlands;
  Terrorism and drugs in Europe.
In addition, a video with subtitles in nine languages, 
including Arabic and Russian, two news releases in 24 
languages (i.e. a taster news release and a highlights 
news release) and a special edition of the newsletter 
Drugnet Europe were produced by the agency to mark 
the launch of the EDMR. A feedback collection from 
audiences has been initiated through a short survey.
‘Meet the authors’ stakeholder event
The EDMR press conference was followed by a dynamic 
EMCDDA-Europol ‘meet the authors’ event, which 
offered around 90 stakeholders the opportunity to 
explore the report ‘hands-on’ with representatives of the 
two agencies.
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Following ‘TED Talk’-style presentations from the 
two directors, the participants were invited to visit 
a ‘thematic marketplace’, which featured parallel 
talks on five topics: impacts, drivers and cross-cutting 
themes; technology-enabled drug markets; markets for 
natural drugs; markets for synthetic drugs and NPS; and 
organised crime. The closing remarks highlighted the 
need to adopt a future-oriented approach in order to 
boost preparedness for potential challenges in the EU 
drug market.
FIguRE 12. Covers of the EDMR 2019 and the 
accompanying highlights for policy and practice
Meet the authors stakeholder event (© EMCDDA, Jonathan Vahsen).
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l  Understanding the nature and consequences of drug-related crime
This is a complex developmental area in which the EMCDDA 
made important progress in 2019. The results of a pilot study 
that was carried out by the agency in Finland, the Netherlands 
and Sweden were published as a supporting paper to the 
EDMR 2019 (see ‘European Drug Markets Report 2019: in 
the spotlight’). This is part of the EMCDDA activity around the 
development and improvement of monitoring drug-related 
crime, with a focus on drug-related homicide. It builds upon 
the 2017 review of the academic research and data sources on 
drug-related homicide at national and European/international 
levels by providing a common definition of the phenomenon 
and a detailed set of guidelines for standardised data 
collection. Importantly, the report also presents a comparative 
analysis of the results of the pilot collection of drug-related 
homicide data conducted in the Netherlands, Finland and 
Sweden.
During the year, the EMCDDA exchanged information with 
drug-related crime expert groups, such as the Expert Group on 
Policy Needs for Data on Crime at the European Commission.
Links between drug trafficking and other crime types such 
as terrorism were explored in the EMCDDA commissioned 
paper Terrorism and drugs in Europe, which accompanied 
the EDMR 2019. Based on the study of a unique open-source 
database, the paper addresses the knowledge gaps in this 
area by empirically examining such crossovers between drug 
trafficking and other crimes in the EU between 2012 and 2017.
In recent years, the EMCDDA has also taken a particular 
interest in understanding the impact on the environment of 
drug production and consumption. In this regard, An analysis 
of the costs of dismantling and cleaning up synthetic 
drug production sites in Belgium and the Netherlands was 
commissioned by the agency and the results were released 
as part of the EDMR 2019 package. This analysis shows 
an increasing trend in the production of synthetic drugs, 
measured by the number of manufacturing sites identified and 
the quantities of drugs seized, with a resulting impact on the 
environment.
Furthermore, the paper Drug precursor developments in the 
European Union was published as part of the EDMR 2019 
package (see ‘European Drug Markets Report 2019: in the 
spotlight’). This paper describes the significant developments 
in the field of drug precursors in the last 5 to 10 years related 
to synthetic stimulant drugs produced in the EU. This includes 
describing the ‘pre-precursor’ phenomenon and responses to 
it, both by the EU and by the drug producers themselves.
l  Supporting EU responses to drug-related security challenges
The EMCDDA provided technical input and advice to its 
key partners, in particular the European Commission, on 
issues such as drug distribution via the internet/darknet 
and cooperation with third countries. At the request of the 
European Commission, the agency also supported the 
informal ‘Internet Forum’ meeting on the online supply of 
drugs, firearms and dangerous chemical substances, which 
was held in Brussels on 18 February. The agency also provided 
input on the European Commission’s proposal for an indicator 
to be used to evaluate funding decisions made in the Internal 
Security Fund 2021-27, which is part of the next multiannual 
financial framework (2021-27) of the EU.
The EMCDDA further supported the work of the Council, which 
included attending meetings of the Standing Committee on 
Operational Cooperation on Internal Security (COSI) (see 
Annex 5 for details). Furthermore, the agency continued 
to contribute to the EMPACT OAPs of the EU Policy Cycle 
on organised and serious international crime. In 2019, this 
included the publication, jointly with Europol, of the EDMR 
2019, the provision of input on the drafting of the EMPACT 
OAPs for 2020 on NPS/synthetic drugs and on cannabis, 
cocaine and heroin, and the organisation of training activities 
for law enforcement professionals with its partner CEPOL. 
To that end, the agency’s staff participated as experts in six 
training initiatives (see Table 1).
TAblE 1. Training initiatives organised with CEPOL in 
2019: activities and number of participants (source: 
CEPOL)
Course Residential participants
Cannabis: production and smuggling 26
Cocaine smuggling 26
Heroin smuggling 26
Drug markets and drug-related crime: 
strategic analysis
35
Dismantling illicit laboratories: advanced 30
Synthetic drugs and NPS 26
Total 169
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In 2019, in partnership with CEPOL, the EMCDDA developed 
and implemented, for the third time, a three-day residential 
training course on ‘Drug markets and drug-related crime: strategic 
analysis’, which was based on the EDMR that was published 
jointly by the EMCDDA and Europol. The course, targeted at senior 
law enforcement personnel, has been successfully certified by the 
International Organization for Standardization (ISO) on ‘Learning 
services outside formal education’ (ISO 29993:2017). The content 
of the 2020 edition of the course will be revised based on the 
latest analysis of the EMCDDA and Europol.
l Main area 3: Business drivers
l Business driver 1: institutional
Governance
The Management Board is the main decision-making body 
of the EMCDDA. It meets twice a year and consists of one 
representative from each Member State of the EU, two 
representatives from the European Commission and two 
independent experts designated by the European Parliament.
Following the fourth external evaluation of the EMCDDA, 
which was carried out by the European Commission in 2018, 
the Commission published a report on 14 May positively 
evaluating the work of the agency.
FIguRE 13. Results of the external evaluation of 
the EMCDDA: quote by EU Commissioner Dimitris 
Avramopoulos
'The EU drugs agency 
has become a genuine 
European hub of 
excellence on the 
increasingly transnational 
challenge of drug use and 
abuse, helping us make 
more informed and more 
effective policies at both 
national and EU level to 
counter the threats and 
harms associated with 
it. I hope in the future the 
agency can further improve 
what it does already both 
within Europe and beyond 
in order to meet the 
challenges ahead.' 
Dimitris Avramopoulos, 
European Commissioner for 
Migration, Home Affairs and 
Citizenship (© EC Audiovisual 
Service).
The report confirms that, over the period 2013-18, the agency 
continued to be widely recognised as a true hub of scientific 
excellence in Europe and internationally, providing factual, 
objective, reliable and comparable data at the European level 
on drugs and drug addiction and their consequences.
The evaluation report and an accompanying staff working 
document, which provides more detailed information, are 
available online.
Subsequently, a follow-up action plan was adopted by the 
EMCDDA Management Board in December. The document 
was drafted by the EMCDDA in a period of budgetary 
uncertainty and the actions envisaged may be overambitious 
should the appropriate resources not be made available to the 
agency. Furthermore, actions were planned taking into account 
the current EMCDDA mandate.
In this overall context, an internal discussion and strategic-
thinking exercise was initiated in 2019 with a view to analysing 
the prospects for the work of the EMCDDA in the future, so 
that it best responds to the evolving needs of its stakeholders 
within the context of a rapidly changing environment and the 
possible impact of ‘megatrends’ (such as digitalisation and 
innovation in monitoring) on the work performed. This analysis 
will be deepened in 2020-21, including an assessment of the 
functioning and suitability of the current business model, with 
possible options to review the analysis in the future identified.
The key decisions taken by the EMCDDA Management Board 
in 2019, together with the activities carried out by the agency 
to support the work of the Management Board Chair and the 
other members of the Management Board, are presented in 
detail in Part II of this report.
Communication and service delivery to meet evolving 
EMCDDA customer needs
The EMCDDA Strategy 2025 sets out a vision for a ‘healthier 
and more secure Europe’ through better informed drug policy 
and action. The strategy states that, to do this effectively, 
we must constantly strive to respond to the needs of our 
key customers. It gives ‘central importance to identifying 
our customers’ needs, developing services and effective 
communication, as these all represent essential elements for 
our work to have impact’.
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To that end, a ‘customer needs project’ was initiated by the 
EMCDDA in 2018, with the overall objective of improving how 
the agency engages with its primary customer groups and 
ensuring that their feedback informs decision-making and 
service development.
A set of qualitative and quantitative techniques were identified 
and tested by the project in 2019, and these will continue 
to be applied in 2020. They include customer journey 
mapping, needs and gap analyses, personas, surveys, online 
consultations, face-to-face (semi-structured) interviews, focus 
groups, workshops, metrics and staff training. Such methods 
will allow the agency to tune into the ‘customer voice’, which 
is essential for embedding and sustaining customer focus and 
service orientation at the EMCDDA. A number of key events 
were selected for the application of these techniques during 
the year, as follows:
  EDR 2019: an online survey to obtain feedback on the 
report ran from 6 June to 31 August and was promoted 
via a range of channels. A report and an infographic were 
created analysing the results.
  A Reitox Academy on communication with national 
policymakers (see ‘Drug policies’ under ‘Main area 
1: Health’): in collaboration with the Spanish NFP, 
a Reitox Academy on communicating with national 
policymakers was organised on 18 and 19 September in 
Madrid. The invitations to the event were accompanied 
by a questionnaire exploring how NFPs currently 
communicate with national policymakers and how they 
provide evidence for the decision-making process. An 
external communications consultant led a session on 
mapping national policymakers, customer journeys and 
building personas. NFPs shared examples of best practice, 
while national policymakers were invited to present 
their experiences and needs. Reports were drawn up 
presenting the lessons learnt from the sessions.
  Training for prevention professionals (see ‘Drug 
interventions’ under ‘Main area 1: Health’): to prepare 
for the discussions at this event, a short online survey 
was sent to the participants ahead of the event and was 
followed up with three focus groups exploring the needs 
of this specific group. A report (with coding tables) was 
drawn up presenting the emerging themes.
  Lisbon Addictions (see ‘Business driver 3: scientific 
capacity’): a paper-based survey entitled ‘Getting to 
know you’ was designed to collect information from the 
participants visiting the EMCDDA stand at this conference 
to build customer ‘personas’. Around 200 responses were 
gathered during the conference. A report analysing the 
results will contribute to the collection of information on 
customers and their needs and will be used for finalisation 
of the customer needs framework.
  EDMR launch (26 November; see ‘Main area 2: Security’): 
an online survey was launched on the day of the report’s 
release. A ‘meet the authors’ stakeholder event was 
organised at the report launch in Brussels.
In parallel with running the customer needs project, the 
EMCDDA’s communication efforts were focused on ensuring 
the production of high-quality publications — a total of 32 
scientific and institutional outputs were launched in 2019.
This was accompanied by activities to enhance engagement 
with the agency’s audience, in particular via the online 
communication channels (see Figure 14 for details).
Over 1.7 million visitors accessed the EMCDDA website in 
2019 (i.e. 4 700 visits per day), an increase of 26 % compared 
with 2018 and of 60 % compared with 2017.
Furthermore, the upwards trend in the number of social 
media followers continued in 2019, with an increase in the 
number of followers observed for all of the channels (i.e. an 
increase in followers of between 7 % for Facebook and 25 % 
for Instagram).
FIguRE 14. EMCDDA online communication channels
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A significant rise in the number of views of EMCDDA videos 
was recorded in 2019, with an overall increase in lifetime views 
of 44.1 % compared with 2018.
Communication metrics were developed and their results were 
disseminated internally on a quarterly basis (see Annex 4).
Engagement with the media also significantly increased in 
2019. The EMCDDA serviced 378 requests from journalists, 
namely 40 % more than in 2018 (272 requests). In addition, 
two press conferences were organised for the launches of 
the EMCDDA flagship reports, namely for EDR 2019 (eight 
journalists) and EDMR 2019 (26 journalists).
In 2019, 12 news releases (which amounted to 84 products 
counting translations), 37 news items and 22 Director’s 
news items were published. In addition, 56 Mailchimp press 
campaigns were launched and 12 Drugnet Europe digital 
newsletter round-ups were produced.
l Business driver 2: partnership
Reitox network activities
The Reitox network was set up in 1993, when the EMCDDA 
was established, and it is composed of NFPs in the EU 
Member States, Norway and Turkey, as well as a focal point 
at the European Commission. The NFPs — from which the 
agency draws the bulk of its data — collect and analyse 
national information on drugs, drawing on various sectors 
including health, justice and law enforcement. They form the 
backbone of the agency’s work.
The activities of the network are defined yearly in the grant 
agreement signed between each NFP and the EMCDDA, while 
the longer term strategic options are guided by the Reitox 
development framework, which was adopted by the network in 
2017.
An important anniversary in the life of the network was 
celebrated in 2019, namely the 60th meeting of the Reitox 
HFPs in Lisbon from 21 to 23 May.
The second annual HFP meeting took place from 13 to 
15 November (which was preceded, on 12 November, as is 
usual for autumn meetings, by an extended network meeting, 
which representatives of third countries also attended). The 
issue focused on in 2019 was the sustainability of the network 
in the context of the challenging financial perspective faced 
by the EMCDDA. In that regard, the HFPs and the agency 
engaged in a dialogue to together identify any possible 
measures to mitigate the impact of resource limitations and to 
ensure the viability of the network, of the EMCDDA and of the 
EU drug-monitoring system in general.
Two technical meetings also took place during the year, on 
19 March and 1 October.
An important means for strengthening the capacity of the 
network continued to be provided by the Reitox Academies 
(see also ‘Main area 1: Health’ and ‘Main area 2: Security’).
Seven Reitox Academies took place in 2019, as follows (see 
also Figure 15):
  ‘Where we are with NPS’ (Vilnius, 24 January): 62 
participants;
  ‘Understanding cannabis policies — changes and 
challenges’ (Lisbon, 20 June): 21 participants;
  ‘National Academy for Latvia: in-depth analysis of cohort 
studies in field of drugs’ (Riga, 7-19 September): seven 
participants;
  ‘Communication: advocacy and stakeholder management’ 
(Madrid, 18-19 September): 21 participants;
  ‘EWS French-speaking academy: Nouvelle directive, nouvel 
outil, nouveaux échanges’ (Paris, 27 November): 39 
participants ;
  ‘National Academy for Austria: online drug purchases 
(cryptomarkets)’ (Vienna, 2 December): 26 participants;
  ‘Synthetic opioids and fentanils (Baltic region)’ (Gdansk, 
12-13 December): 28 participants.
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FIguRE 15. Reitox Academies 2019
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The information brochure The Reitox network: frequently asked 
questions was published in October. It provides answers to 
the most commonly asked questions on the Reitox network 
of NFPs and more broadly on national drugs observatories. 
Compiled over several years, it is a reference tool for both EU 
Member States and countries further afield as regards the 
network, its members, its role and its development. The Reitox 
network also actively participated in the Lisbon Addictions 
conference (see ‘Business driver 3: scientific capacity’). Among 
the activities led by the Reitox network were a structured 
session on ‘Drug policy debates: how are routine monitoring 
data used?’ and a Reitox posters session.
The EMCDDA certification of Reitox NFP quality was adopted 
by the Reitox NFPs network in 2019. The Reitox certification 
acknowledges the competence of an EMCDDA NFP to carry 
out specific tasks in a reliable/credible/accurate manner 
and that it meets the minimum criteria for the fulfilment of 
the tasks of an NFP as set out in Article 5 of the EMCDDA 
Regulation.
An important part of the EMCDDA’s work with the network 
is related to the management of the Reitox grants. The 
2019 grant applications were assessed and grants were 
awarded, committed and signed, for a total value of more than 
EUR 2 million.
In parallel, from March to November, all of the financial and 
narrative reports related to the 2018 grants were analysed, all 
of the balance payments were executed and the grants were 
subsequently closed, in line with the applicable procedure. 
Field verifications (on-site audits) were carried out by the 
EMCDDA at the headquarters of two NFPs, namely the 
Lithuanian NFP (16-20 September) and the Spanish NFP 
(28-30 October).
Cooperation with EU agencies and international partners
Cooperation with EU agencies was further strengthened in 
2019.
Two new working arrangements were signed in Brussels, on 
12 February, between the EMCDDA and ECHA and between 
EFSA. The EMCDDA Director, Alexis Goosdeel, signed the 
agreements with ECHA Executive Director Bjorn Hansen 
and EFSA Executive Director Bernhard Url. The agreements 
will ensure that the agencies exchange information on 
NPS, in accordance with their mandates and in line with 
new legislation that has applied since November 2018 
(see ‘Responding to new psychoactive substances: EU Early 
Warning System and risk assessment’ under ‘Main area 1: 
Health’).
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Signing of the working arrangements between the EMCDDA and EFSA (left: Bernhard Url, EFSA Executive Director (left) and Alexis Goosdeel, EMCDDA 
Director (right)) and the EMCDDA and ECHA (right: Bjorn Hansen, ECHA Executive Director (left) and Alexis Goosdeel, EMCDDA Director (right)).
These two new working arrangements follow the ones signed 
in 2018 with Europol, the ECDC and the EMA for implementing 
the new legal framework.
On 7 March, the EMCDDA Director welcomed Dr Andrea 
Ammon, Executive Director of the Stockholm-based ECDC, on 
a visit to the EMCDDA.
In addition to the implementation of the EU EWS, the EMCDDA 
collaborates with the ECDC on a number of projects, including 
joint guidelines, missions to assess HIV outbreaks at the request 
of Member States, the UN Sustainable Development Goals for 
hepatitis reduction, the Dublin Declaration goals on HIV, and 
sharing data and expertise. The EMCDDA provides expertise to 
and shares information with the ECDC on the extent and impact 
of disease in the sub-population of drug users.
In particular, in 2019, these agencies worked closely together to 
strengthen the European monitoring framework for hepatitis in 
Europe. The ECDC launched an HCV prevalence database, which 
contained references to the EMCDDA datasets for PWID, and 
the EMCDDA drafted a technical paper on a hepatitis barometer, 
which was reviewed by the ECDC expert. The agencies also 
organised a joint session at the Lisbon Addictions conference on 
‘National continuums of care for HIV and hepatitis B and C’.
Close collaboration also took place through participation in 
the expert meetings and advisory committees of the agencies, 
including at the EMCDDA drug-related infectious diseases 
expert meeting in October; the EMCDDA also participated 
in the European hepatitis C prevalence survey (SPHERE-C) 
expert meeting at ECDC in April.
Dr Andrea Ammon, ECDC Director (left), and Alexis Goosdeel, EMCDDA 
Director (right).
Some of the EMCDDA’s other key partners are Europol and 
CEPOL (see also ‘Main area 2: Security’). Cooperation with 
Europol continued to focus on the exchange of strategic 
information, methodologies and technical expertise; the 
production of joint strategic analyses and threat assessments; 
the development of joint reporting tools; the delivery 
of joint training activities; and actions in support of the 
implementation of the new NPS legislation. A key outcome 
of the collaboration between the two agencies was the joint 
EMCDDA-Europol EDMR 2019.
Intensive cooperation and coordinated work also took place in 
the framework of the EU Policy Cycle on organised and serious 
international crime. In the framework of EMPACT, joint work on 
developing and improving the drug-related reporting tools on 
synthetic drugs, cocaine and cannabis took place, and training 
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delivered to Member States was conducted jointly by Europol, 
the EMCDDA and CEPOL. In 2019, the EMCDDA participated 
in five technical meetings of EMPACT.
Based entirely on the joint EMCDDA-Europol publication of the 
EDMR in 2016, the EMCDDA, in collaboration with CEPOL and 
supported by Europol, developed a residential training course 
that was delivered in Portugal in June entitled ‘Drug markets 
and drug-related crime — strategic analysis’.
Overall, CEPOL, the EMCDDA and Europol developed seven 
training modules (courses, programmes, webinars and online 
modules) — with CEPOL leading five and the EMCDDA and 
Europol leading one each — related to, among other topics, 
the EU EWS, NPS, heroin and cocaine smuggling, synthetic 
illicit laboratories dismantling, and synthetic drugs.
In addition, the EMCDDA contributed to CEPOL’s stakeholder 
needs assessment through various tools and exercises.
On 28 May, the EMCDDA received a visit from Mr Detlef 
Schröder, Director of CEPOL, and Mr Peter Stauber, Policy 
Officer. During the meeting, the representatives of the two 
agencies discussed their cooperation.
Cooperation with other EU agencies also took place in the 
framework of the specialised networks, such as EU-ANSA, 
the Justice and Home Affairs (JHA) agencies’ network, 
the Performance Development Network, the Heads of 
Communication and Information Network and other technical 
networks in which the EMCDDA is represented.
In 2019, the EMCDDA contributed to technical discussions 
with international partners, in particular with the UNODC and 
the WHO, on how to improve data collection and on how to 
facilitate inter-agency collaboration. The EMCDDA is an active 
member of the international expert working group on drug 
epidemiological statistics led by the UNODC and the WHO. 
The EMCDDA was invited to the third meeting of the Scientific 
Advisory Committee of the World Drug Report in September, 
and the agency contributed to various technical meetings (see 
‘Main area 1: Health’, ‘Main area 2: Security’ and Annex 5 for 
details). A joint publication from the EMCDDA and the UNODC 
was published on 27 February, presenting the key findings 
from surveys of drug-treatment facilities carried out in four 
Western Balkan countries in 2017. The results provide insights 
into the characteristics and capacity of the treatment systems 
in these countries and present conclusions and implications 
for policy and practice.
The EMCDDA continued to cooperate with both the WHO 
headquarters (Geneva) and the WHO Regional Office for 
Europe (WHO/Europe, Copenhagen) in the areas of quality 
standards of interventions and the monitoring of treatment 
systems, and prison and infectious diseases.
The EMCDDA, WHO/Europe and the ECDC have been 
working closely to assist countries in the elimination of viral 
hepatitis in line with the WHO hepatitis elimination agenda. 
The agencies are contributing to the development of the 
European hepatitis monitoring framework by contributing to 
expert meetings, conferences and technical work. In 2019, the 
EMCDDA participated in the first Regional Consultation on 
Viral Hepatitis in the WHO European Region: Progress on the 
Way to Elimination, which took place in Tbilisi, Georgia, on 12 
and 13 February, and attended the bilateral meeting between 
the European Commission and WHO/Europe on strengthening 
the collaboration in enlargement countries, ENP countries and 
Central Asian countries.
Cooperation also continued with regional organisations. In 
May, the EMCDDA Director met in Lisbon with Denis Huber, 
the Executive Secretary of the Council of Europe Pompidou 
Group to discuss the Pompidou Group work programme 
2019-22 and its cooperation and coordination with EMCDDA 
activities, as well as the Pompidou Group statutory revision 
process. The cooperation areas include drug policies, precursor 
control, prison, cybercrime, cooperation with non-EU countries 
and support for training. Among others, in 2019, the EMCDDA 
participated in an executive training course for drug policy 
managers on incorporating gender dimensions in drug policy 
practice and service delivery (June) and in a seminar on 
responding to drug-related challenges for refugees, migrants 
and internally displaced people (October).
On 13 March, Ambassador Adam Namm, Executive Secretary 
of the Inter-American Drug Abuse Control Commission 
(CICAD) of the Organization of American States, visited 
the EMCDDA to discuss with the agency’s Director, Alexis 
Goosdeel, perspectives on the next EMCDDA-CICAD work 
programme (2019-23) ahead of the signing of the document, 
which took place in January 2020 in Washington, DC.
In terms of cooperation with third countries, at the technical 
level, this was mainly carried out within the EU-funded 
technical cooperation projects IPA 6, IPA 7 and EU4MD 
(see later section on cooperation with third countries in the 
framework of the EU-funded technical assistance projects).
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At the institutional level, work was guided by the EMCDDA 
International Cooperation Framework, which was adopted in 
2017.
In this respect, the EMCDDA and Albania will cooperate 
more actively on monitoring the drug phenomenon in future, 
thanks to a working arrangement concluded on 13 March in 
Vienna. The agreement was signed by EMCDDA Director Alexis 
Goosdeel and by the Albanian Deputy Ministers of the Interior 
and of Health and Social Protection, in the presence of Dimitris 
Avramopoulos, the European Commissioner for Migration, 
Home Affairs and Citizenship. The signing ceremony took place 
at the Delegation of the EU to the International Organisations 
in Vienna and was hosted by EU Ambassador Didier Lenoir.
In June, the EMCDDA Management Board also gave the 
EMCDDA Director the mandate to sign the newly negotiated 
working arrangement with Ukraine and to negotiate further 
working arrangements with Algeria, Kosovo (3) and Serbia, at 
the requests of these countries.
Cooperation with third countries in the framework of the 
EU-funded technical assistance projects
Enlargement countries
In 2019, cooperation with the EU enlargement countries 
mainly took place in the framework of the technical 
cooperation projects for IPA beneficiary countries, namely 
IPA 6 (until June) and the new IPA 7 project, which started on 
1 July.
Over the final six months of implementation of the IPA 6 
project, the EMCDDA organised the third and final IPA 6 
project steering committee meeting, at which representatives 
from the European Commission’s DG NEAR, representatives of 
the permanent missions and national correspondents from the 
beneficiaries participated.
Apart from the attendance of national experts from EU 
enlargement countries at the EU key indicator expert meeting 
on ‘Prevalence and patterns of drug use among the general 
population’, the EMCDDA also organised a training session on 
communication issues (focusing on how to improve skills in 
the formulation of drug-related messages within the partner 
(3) This designation is without prejudice to positions on status, and is in line 
with uN Security Council Resolution 1244/1999 and the International Court 
of Justice Opinion on the Kosovo declaration of independence. Applies to all 
mentions of Kosovo in this document.
From left to right: Besfort Lamallari, Albanian Deputy Minister of the 
Interior; Mira Rakacolli, Albanian Deputy Minister of Health and Social 
Protection; Dimitris Avramopoulos, European Commissioner for Migration, 
Home Affairs and Citizenship; Alexis Goosdeel, EMCDDA Director 
(© European Commission).
institutions) for eight participants and a practical hands-on 
training session for law enforcement agencies from the 
EU enlargement countries on data collection and reporting 
on drug seizures. By the end of June, all beneficiaries had 
provided the EMCDDA with drugs seizures data for the period 
2016-17, albeit not all in line with the EU protocol.
Serbia, being more advanced in setting up a national EWS, was 
the only EU enlargement country to attend the 19th Annual 
Meeting of the Reitox Early Warning System Network. The 
Serbian national EWS profile was published on the EMCDDA 
website.
On 6 June, the EMCDDA organised — jointly with the 
representatives of the Romanian National Anti-drug Agency — 
the final IPA 6 wrap-up meeting in Bucharest, which was 
followed by the official launch of the EMCDDA EDR 2019 
and which was also attended by representatives of the EU 
enlargement countries.
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A follow-up technical cooperation project between the 
EMCDDA and candidate and potential candidate countries — 
IPA 7 — started on 1 July. The project, entitled ‘Stepwise 
integration of the IPA beneficiaries in the activities of the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and the Reitox network’, aims to enhance the 
capacity of the EU and the IPA beneficiaries to detect, analyse 
and report on emerging drug-related health and security 
threats. It will cover a period of 36 months and will have 
a total earmarked budget of EUR 1 million. The beneficiaries 
of this technical cooperation project are Albania, Bosnia and 
Herzegovina, Kosovo, Montenegro, North Macedonia and 
Serbia.
The first official visit organised within the project took place in 
Montenegro, on 17 and 18 July, where the EMCDDA Director 
met several high-level dignitaries working in the drugs field 
(see ‘EMCDDA Director: main activities’ under ‘Business driver 
4: management’).
Selected national experts from candidate and potential 
candidate countries were invited to attend the EU expert 
meetings of three out of five key epidemiological indicators, 
namely the drug-related infectious diseases indicator (DRID) 
on 8 and 9 October, the drug-related deaths indicator (DRD) 
on 21 and 22 October and the treatment demand indicator 
(TDI) on 27 and 28 November. During each of these meetings, 
the IPA 7 team organised specific satellite meetings with the 
experts from the IPA beneficiaries to discuss their available 
national datasets and other information sources in the area of 
the key epidemiological indicators concerned.
During the Third European Conference on Addictive 
Behaviours and Dependencies from 23 to 25 October, the 
EMCDDA IPA 7 project team organised a networking event 
targeted at participants from the Western Balkans and 
financed the participation of an Albanian expert at the 
conference. At the event, the IPA 7 team presented the new 
project and encouraged the establishment of synergies with 
several partner organisations.
IPA 6 achievements in a nutshell
The following are the key achievements of the IPA 6 
project:
  an increased availability of data in the health and 
security/supply fields, which paved the way for 
setting up broader objectives in the next project;
  the first nationwide general population survey 
implemented in Bosnia and Herzegovina — in 
line with the EMCDDA standards — with results 
presented to the national stakeholders in Sarajevo 
and also made available on the EMCDDA website 
in 2019;
  implementation of ESPAD in Kosovo, Montenegro, 
North Macedonia and Serbia, thanks to co-financing 
between a specific EMCDDA budget and national 
authorities;
  the publication, in February 2019, of the joint 
EMCDDA-UNODC report entitled Drug treatment 
systems in the Western Balkans, presenting 
a summary of the key findings from drug-treatment 
facility surveys carried out in 2017 in Albania, 
Bosnia and Herzegovina, Kosovo and Serbia and 
considering the implications for practice and 
policy — the results provide insights into the 
characteristics and capacity of the treatment 
systems, as well as the availability and provision of 
treatment interventions;
  assessment visits to Serbia and Montenegro 
to evaluate their readiness for participating 
in the agency’s work and in particular on the 
establishment of an operational national drugs 
observatory and a national EWS — the output 
of these visits was a report summarising the 
observations and recommendations from the 
EMCDDA to both countries to further strengthen 
their national drug-monitoring systems;
  consolidation of institutional cooperation through 
the organisation of national stakeholder meetings 
in the capital city of each beneficiary, which 
ensured that the project’s objectives and outcomes 
complemented national plans and roadmaps — 
countries are working on updating their national 
information maps, which are tools to identify and 
describe all drug-related data sources;
  the signing of a working arrangement with the 
Ministry of Interior and the Ministry of Health and 
Social Protection of Albania.
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EU4Monitoring Drugs (EU4MD): in the spotlight
In 2019, the EMCDDA launched a three-year project 
worth EUR 3 million, EU4MD, which will intensify its 
cooperation with the countries of the ENP.
The EU-funded project, running until the end of 2021, 
supports national and regional readiness in the ENP 
area to identify and respond to drug-related health and 
security threats. While fostering regional cooperation 
and cooperation between the ENP and the EU, the 
EU4MD project:
  helps beneficiary countries be better prepared to 
respond to existing and future drug-related threats 
through capacity building and partnerships;
  facilitates the identification, understanding and 
reporting of new and emerging drug-related threats 
and the analysis of their implications for security 
and health;
  supports a strategic analysis of developments in 
the drug market and how these affect security and 
health.
Networking and partnership are central to EU4MD. The 
project deploys a participatory approach to capacity 
building (‘learning by doing’) and activities focus on 
developing practical and scientific knowledge, along 
with the skills of professionals and organisations.
The potential beneficiaries of the project are Algeria, 
Armenia, Azerbaijan, Belarus, Egypt (4), Georgia, Israel, 
Jordan, Lebanon, Libya, Moldova, Morocco, Palestine, 
Tunisia and Ukraine.
During the first year, technical assessment visits to eight 
countries were conducted (see Figure 16 for details), in 
which a team of security and health experts met with 
a range of stakeholders from law enforcement, health 
and justice administrations and services, EU delegations, 
national and international non-governmental 
organisations (NGOs) and other international partners.
These visits provided the basis for capacity-building 
and threat assessment activities. Based on these visits, 
a capacity development plan for the project was defined 
and 87 professionals took part in one or more of the 14 
capacity-building activities that were carried out in 2019. 
In addition, the EMCDDA contributed to some further 
10 capacity-building activities targeting ENP countries, 
which were implemented by European and international 
partners.
Furthermore, national ESPAD studies were implemented 
in Georgia and Ukraine, and preparations were made 
to undertake data-collection and analysis activities 
on cannabis trafficking routes, treatment systems and 
national drug policies.
(4) In August, the EMCDDA was informed that the competent authorities of 
Egypt had decided not to participate in the project.
The first project coordination meeting took place in Lisbon 
on 11 November during the Eighth Extended Reitox Network 
Meeting, with all of the IPA beneficiaries participating.
In November, the Ministry of Health of Montenegro and the 
Organization for Security and Co-operation in Europe Mission 
to Montenegro co-organised a regional meeting on the ‘Global 
challenge and threat to the safety and health of societies — 
emergence of new psychoactive substances’, at which an 
EMCDDA staff member presented the EU EWS as a tool for 
protecting public health.
During the first six months of the EMCDDA IPA 7 project, the 
progress achieved was monitored through regular internal 
and external project management and inter-institutional 
coordination meetings and through dialogue and coordination 
with the European Commission services, EU delegations in 
the region and national authorities. By the end of the year, the 
EMCDDA had carried out an update of the national roadmap 
of each IPA beneficiary, which was shared with the national 
authorities and the European Commission services concerned.
EU neighbouring countries
Cooperation with neighbouring countries took place within 
the framework of the EU4MD project, funded by the European 
Neighbourhood Instrument.
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FIguRE 17. EU4MD project: multilingual branding
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FIguRE 16. EU4MD 2019: main events
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Lebanon
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Technical visit to 
Ukraine
13-16 May
Technical visit  to 
Moldova
1-5 July
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on European prevention 
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Vienna
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Commission services, 
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First Advisory 
committee meeting, 
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26 November
Multi-country 
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Another third country with which the EMCDDA strengthened 
its institutional cooperation in 2019 was Russia. In July, the 
EMCDDA Director paid an official visit to Moscow and met 
representatives from the Main Directorate for Drug Control 
of the Ministry of Internal Affairs of the Russian Federation; 
Mr Dmitry Kostennikov, the Deputy Minister of Health of the 
Russian Federation; and representatives from the National 
Research Institute of Narcology.
l Business driver 3: scientific capacity
The multifaceted nature of the drugs situation requires the 
EMCDDA to have both sufficient in-house expertise and 
access to experts working elsewhere to ensure adequate 
scientific capacity for this work. In 2019, the agency 
strengthened its ongoing dialogue with the research and 
scientific community.
Scientific Committee activities
As the guardian of the EMCDDA’s reputation for scientific 
excellence, the Scientific Committee plays a key role in 
assuring and improving the quality of the work carried out by 
the agency.
On 13 December, the EMCDDA Management Board appointed 
15 high-level scientists to serve on the agency’s Scientific 
Committee for the period 2020-22. The selection followed 
a call for expressions of interest in the Official Journal of the 
European Union, which yielded 78 eligible applications. The 
Management Board also approved a list of experts to be called 
upon by the EMCDDA Director for the purposes of assessing 
the risks posed by NPS — one of the agency’s core tasks (see 
Main area 1: Health).
During the year, the members of the Scientific Committee 
adopted a formal opinion on the EMCDDA’s PD 2020-22, and 
provided input on the agency’s main projects and scientific 
publications, in line with the guiding principles for the review 
of selected publications. The Scientific Committee also 
contributed to the HDG’s annual dialogue on research.
In 2019, the EMCDDA continued to investigate ways to further 
increase the quality of its analyses and outputs across all key 
areas of work. Efforts focused on implementing the action 
plans that were put in place to address the recommendations 
of the European Commission’s Internal Audit Service (IAS) 
on the management of data collection, validation and quality 
assurance (2017) and publications management (2018).
Lisbon Addictions 2019: in the spotlight
World experts reviewed the future of addictions at the 
Third European Conference on Addictive Behaviours 
and Dependencies, which took place in Lisbon from 
23 to 25 October.
For the 2019 conference, a new ‘co-production’ 
approach was used to shape the conference programme, 
aiming to develop a diverse and innovative event. The 
six ‘co-producers’ were the European Federation 
of Addiction Societies (EUFAS), the International 
Network on Hepatitis in Substance Users (INHSU), 
the International Society for the Study of Drug Policy 
(ISSDP), the International Society for the Study of 
Behavioural Addictions (ISSBA), the Society for the 
Study of Addiction and the EU-funded project FuturiZe. 
Each ran a programme of activities built around selected 
topics (thematic ‘tracks’).
FIguRE 18. Lisbon Addictions 2019: quote by Manuel 
Cardoso, SICAD Deputy General Director, and Paul 
Griffiths, EMCDDA Scientific Director
‘The focus of #LxAddictions19 is the future of addictions. The sessions 
held over the next three days will encourage us all to consider how 
adopting better practice, science and methods in the addictions field 
can help contribute to an improved society. We recognise that the 
issues that shape the future, both in the addictions area and more 
generally, are often interlinked.’  
Source: LxAddictions Magazine.
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The FuturiZe ‘track’ activities were hosted in the Futures 
Zone, where sessions focused on forward-looking 
trends and topics, including digitalisation, future drug 
policy, innovative monitoring and new therapeutic 
horizons. FuturiZe was a European project, co-funded 
by the European Commission’s Directorate-General 
for Migration and Home Affairs (DG HOME) under the 
Justice programme, which aimed to provide a space 
for EU-wide, multi-stakeholder and inter-sectoral 
networking and structured interactive debates. This 
project offered bursaries to 120 professionals who 
would otherwise not have been able to attend the event.
A record of 1 300 participants — researchers, 
practitioners and policy experts from all over the 
world and a range of specialist areas — attended the 
event. The 2019 conference focused on the ‘Future of 
addictions: new frontiers for policy, practice and science’ 
and offered high-level content tracks, large-scale 
debates and various session formats, along with guided 
poster tours. The conference programme contained 
850 presentations distributed over 150 sessions and 
showcased 264 e-posters.
Four side events also took place ahead of the 
conference:
  the International Symposium on Drug Checking;
  the Ninth Symposium of the Alcohol Policy Network 
in Europe (APN);
  ‘Health Without Barriers’ — the Second European 
Conference on Healthcare in Prison;
  the International Cannabis Toolkit Workshop.
EMCDDA experts played an active role in the 
conference, delivering over 60 presentations and 
e-posters, which covered topics ranging from the 
challenges of monitoring new drugs to drug-checking 
technology and HCV testing and care.
Winners of the 2018 EMCDDA scientific award were 
invited to present their articles during the Lisbon 
Addictions 2019 conference (5). The prize, inaugurated 
in 2011 by the EMCDDA and its Scientific Committee, 
celebrates scientific writing and distinguishes high-
quality research in the field of illicit drugs.
The success of the conference is reflected in the 
satisfaction expressed by participants who took part 
in our feedback survey. The most common strengths 
identified by the respondents to the survey were 
the multidisciplinary character of the conference, 
with a broad range of topics, and the quality of the 
programme, topics chosen and speakers.
The event also had a strong presence on social media, 
with more than 5 000 tweets and close to 40 million 
Twitter impressions.
(5) The five winners (primary authors) were Professor Dr Christian büchel 
(germany), Judit Tirado Muñoz, PhD (Spain), Daan van der gouwe (the 
Netherlands), Professor John Marsden (the united Kingdom) and Vendu-
la belackova, PhD (Czechia).
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l Business driver 4: management
EMCDDA Director: main activities
The Director, through his external activities, contributed to 
increasing the visibility of the EMCDDA and consolidating the 
credibility of its work by building and improving partnerships 
(for further details, see also ‘Main area 1: Health’ and ‘Main 
area 2: Security’).
The purpose of these activities was twofold: to provide 
information on the performance of the EMCDDA in delivering 
on its mandate and implementing its annual work programme 
and to communicate the scientific evidence resulting from the 
agency‘s monitoring and analytical work.
These high-level communication efforts, which involved some 
30 missions carried out by the EMCDDA Director during the 
year, were focused on the agency’s key customers, namely 
drug policymakers at the EU and Member State levels and the 
practitioners working in the field. Important institutional visits 
and exchanges also took place with high-level representatives 
of some international organisations and third countries.
EU bodies
In terms of the EMCDDA’s relationship with EU policymakers, 
the Director further strengthened relationships with the 
European Parliament. He gave presentations at two meetings 
of the LIBE Committee of the European Parliament: on 
19 February, he presented the EMCDDA’s performance in 2018 
and an outlook on activities for 2019 and, on 4 September, 
the Director attended a meeting of the new LIBE Committee 
(following the European Parliament elections in May 2019), 
during which the directors of JHA agencies presented the work 
and the activities of their agencies. The Director presented the 
mandate of the EMCDDA, the drug situation in Europe based 
on the EDR 2019, the main achievements in 2018 based on 
the last General Report of Activities and key challenges for the 
future.
In addition, throughout the year, he had meetings with several 
Members of the European Parliament and with members 
of the LIBE Committee, the Committee on the Environment, 
Public Health and Food Safety and the Committee on Budgets, 
namely on issues concerning the work of the agency and the 
budgetary needs for 2020.
Concerning the Council, on 8 and 9 July, the Director 
participated in an informal meeting of COSI of the Council, 
in The Hague. Furthermore, Mr Goosdeel participated in 
the Western Balkans JHA ministerial forum in Skopje, North 
Macedonia, on 18 and 19 November. On this occasion, 
the Director gave a presentation on the challenges of and 
perspectives on cooperation on drugs between the EMCDDA 
and the Western Balkans.
The Director had regular meetings throughout the year with 
the European Commission’s services. This included meetings 
with the Cabinet of Commissioner Avramopoulos and with 
the Director-General, Paraskevi Michou, and Deputy Director-
General, Olivier Onidi, of DG HOME. Mr Goosdeel met on 
5 June with Commissioner Carlos Moedas, responsible for 
research, science and innovation, in Brussels. He also had 
a meeting with members of the Cabinet of Commissioner 
Vytenis Andriukaitis to provide an update on the EMCDDA’s 
work in the area of public health. He met on several occasions 
with Ms Floriana Sipala, Head of the Organised Crime and 
Drugs Policy Unit at DG HOME.
The Director participated on 7 June in the formal meeting of 
the Steering Group on Health Promotion, Disease Prevention 
and Management of Non-Communicable Diseases, chaired 
by the Deputy Director-General for Health of the Directorate-
General for Health and Food Safety (DG SANTE). He also met 
on this occasion with Mr John F. Ryan, Director for Public 
Health, Country Knowledge, Crisis Management at DG SANTE.
With regard to building relationships with the other EU 
agencies, the Director participated in the meeting of the heads 
of JHA agencies, on 22 November, at Europol in The Hague, as 
well as in the meeting of heads of EU agencies on 13 February 
in Brussels. During the meeting, the Director signed the 
working arrangement between the EMCDDA and EFSA, further 
to Regulation EU 2017/2101 on the Early Warning System on 
NPS, with the Executive Director of EFSA, Mr Bernhard Url.
Further to the same regulation (EU 2017/2101), the Director 
also signed the working arrangement between the EMCDDA 
and ECHA with the Executive Director of ECHA, Mr Bjorn 
Hansen.
The Director welcomed Ms Andrea Ammon, Director of the 
ECDC, and Ms Maarit Kokki, Head of Section for International 
Relations, at the EMCDDA on 7 March to discuss enhancing 
collaboration in different areas of work. The Director of CEPOL, 
Mr Detlef Schröder, and Mr Peter Stauber, Policy Officer, paid 
a visit to the EMCDDA on 28 May.
The Representation of the European Commission and 
European Parliament in Portugal, the Municipality of Lisbon, 
the European Maritime Safety Agency (EMSA) and the 
EMCDDA jointly organised an exhibition to promote the 
cleaning of the seas and to raise awareness about pollution 
of the seas and its effects. The Director participated in the 
inauguration of a children’s photograph exhibition entitled ‘I 
live by the sea’ at Praça de Europa, Lisbon, on 2 May, in the 
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presence of the European Commission’s Vice-President for 
Jobs, Growth, Investment and Competitiveness, Jyrki Katainen.
The EMCDDA Director participated in the Ministerial Segment 
of the 62nd Session of the CND on 14 and 15 March and in the 
CND meeting on 18 March, organised by the UNODC in Vienna.
EU Member States
In recognition of, and appreciation for, its work over the past 20 
years, the EMCDDA was awarded a Gold Medal of the Order 
of Merit of the Spanish national plan on drugs (Delegación del 
Gobierno para el Plan Nacional sobre Drogas — DGPNSD). 
The Director received the medal on behalf of the agency 
from Minister María Luisa Carcedo, on 9 January, at the 
Ministry for Health, Consumer Affairs and Social Welfare in 
Madrid. Following a presentation by the new Delegate of the 
DGPNSD, Ms Azucena Martí Palacios, Mr Goosdeel also gave 
a speech on the same day at the Spanish Reitox NFP on ‘New 
challenges in the area of drugs in Europe’.
The Director paid an official visit to Latvia in April. The visit 
included meetings with the Minister and representatives of 
the Ministry of Health and of the Ministry of Interior, a visit to 
the Centre for Disease Prevention and Control (the Latvian 
NFP), a visit to the Centre of Addiction of the Olaine Prison 
outside Riga and discussions with representatives from NGOs, 
the Parliament and the Latvian Medical Association on the 
legalisation of cannabis for medical purposes.
The Director participated in a visit to EMSA of Her Excellency 
Ms Kolinda Grabar-Kitarović, President of the Republic of 
Croatia, on 27 May.
Speaking at the opening session of the 2019 International 
Conference on Drug Prevention, Treatment and Care — 
Inspiration and Direction, organised in Vienna from 1 to 
5 July by ISSUP, Mr Goosdeel presented the latest demand 
reduction trends and developments in Europe. During this 
conference, the Director had a meeting with Dr Brigitte 
Zarfl, Federal Minister of Labour, Social Affairs, Health and 
Consumer Protection of Austria.
The Director participated in the First Scientific Conference on 
Addiction in Nicosia, Cyprus, on 11 and 12 September, during 
which he met with the Minister of Health, Mr Konstantinos 
Ioannou, the Chairman of the National Addictions Authority, Mr 
Chrysanthos Georgiou, and the members of the Cyprus Anti-
Drugs Council and representatives of Cyprus on the EMCDDA 
Management Board.
During a visit to Greece from 17 to 20 September, the Director 
gave a lecture to the students of the Post-graduate Diploma on 
Addictions at the Athens University School of Medicine. Upon 
invitation by the Hellenic Police, Mr Goosdeel paid an official 
visit to the Tripartite Centre between Bulgaria, Greece and 
Turkey, which is located at the border crossing point of Kapitan 
Andreevo. Finally, Mr Goosdeel gave a keynote lecture at the 
17th European Federation of Therapeutic Communities (EFTC) 
Conference, which took place on 19 and 20 September in 
Thessaloniki, Greece.
During his official visit to Croatia in November, Mr Goosdeel 
met with the Secretaries of State of the Ministry of Interior and 
the Ministry of Health, and presented the main findings of the 
2019 EDMR to the Committee on Health and Social Policy of 
the Croatian Parliament.
In the framework of relations with the authorities of the 
agency’s hosting country, the Director attended the 
inauguration ceremony of the new space of the Portuguese 
NGO ‘GAT IN Mouraria’ (Grupo de Ativistas em Tratamentos — 
GAT) in Lisbon on 21 January. GAT is a non-profit NGO, with 
Private Institution of Social Solidarity on Health status, based 
in Lisbon. GAT is the Portuguese member of the European 
Civil Society Forum, a think tank on HIV/AIDS of the European 
Commission that is recognised by WHO/Europe, the ECDC, 
the EMCDDA and the Joint UN Programme on HIV/AIDS 
(UNAIDS).
Mr Goosdeel met with Professor Dr Rui Tato Marinho, Head 
of the Department of Gastroenterology and Hepatology at the 
Hospital Santa Maria, in Lisbon on 10 April to discuss the care 
of substance users with hepatitis, and visited the facilities.
The Director attended UNITE’s Joint Action Policy Day in Porto 
on 27 April and co-chaired a session on ‘Global picture on 
opportunities and lessons to learn to scale up harm reduction’. 
UNITE is a non-profit and non-partisan development NGO 
created in 2017 by Dr Ricardo Baptista Leite, a member of the 
Portuguese Parliament, with the support of UNAIDS.
The Director participated on 7 May in a conference organised 
by SICAD of the Portuguese Ministry of Health on the occasion 
of the 20th anniversary of the national strategy of the fight 
against drugs, at the Gulbenkian Foundation.
SICAD, the Policia Judiciária of Portugal and the UNODC 
organise, every two years, a meeting of Heads of National 
Drug Law Enforcement Agencies (HONLEA). The Director 
participated in the meeting organised last year in Lisbon, 
which included a visit to the EMCDDA on 5 July. He made 
a speech on ‘EMCDDA and its role in contributing to a more 
secure Europe’ to an audience of about 100 participants.
The President of Portugal, Marcelo Rebelo de Sousa, visited the 
EMCDDA on 10 July. The Director presented an insight into the 
work of the agency and the latest trends and developments 
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in the drug situation in Europe and Portugal. This was the 
President’s first visit to the EMCDDA since he took office.
Mr Goosdeel participated in several events organised by 
the Portuguese authorities, had bilateral meetings with EU 
Member State ambassadors and attended a number of 
receptions held to mark national days at the embassies of 
various EU Member States and non-EU countries.
International organisations and third countries
The Director gave a presentation at the Final Conference of 
the Solidify Project, which took place on 5 and 6 December at 
the EMCDDA (see ‘Main area 1: Health’). On this occasion, Mr 
Goosdeel had a bilateral meeting with Dr Ruth Dreifuss, former 
President of the Swiss Confederation and Chair of the Global 
Commission on Drug Policy.
Ms Michelle Bachelet, UN High Commissioner for Human 
Rights, visited the EMCDDA on 29 April together with Ms 
Marta Temido, Minister of Health for Portugal. The importance 
of treating drug users with dignity through the provision of 
treatment and harm reduction measures was highlighted in 
the discussions.
His Excellency Ambassador Adam E. Namm, Executive 
Secretary of CICAD, visited the EMCDDA on 12 March. An 
exchange of views took place on the state of cooperation 
between the EMCDDA and CICAD, in particular on the 
implementation of the work programme for 2014-18 and the 
preparation of the work programme for 2020-24.
Mr Denis Huber, Executive Secretary of the Pompidou Group of 
the Council of Europe, paid an official visit to the EMCDDA on 
27 May to discuss ways of strengthening cooperation between 
these organisations. The Director also participated in the 84th 
Meeting of the Permanent Correspondents of the Pompidou 
Group in Lisbon on 29 May.
Mr Goosdeel met with the members of the public committee 
on the Norwegian drug policy reform on 6 February at the 
EMCDDA. The objective of the visit was to learn about the 
recent trends in European and global drug use and on the 
drug market, as well as the development of international drug 
policy. Another issue discussed was the police’s role, attitudes, 
strategies and experiences related to law enforcement of the 
Portuguese drug decriminalisation policy.
FIguRE 19. Twitter post by the Deputy Chief Negotiator for 
Montenegro’s accession to the EU
The Director paid his first official visit to Montenegro on 17 and 
18 July, where he met with the Montenegrin Minister of Health, 
Dr Kenan Hrapović, and representatives of the Prime Minister’s 
office, the Ministry of the Interior, the National Statistical Office 
and the Institute for Public Health. The EMCDDA delegation 
also met with the Head of the EU Delegation in Montenegro, 
Ambassador Aivo Orav.
The Deputy Chief Negotiator for Montenegro’s accession to the 
EU posted on Twitter about the meeting (see Figure 19).
The Director and other representatives of the EMCDDA met 
with officials of the General Directorate for Drug Control of 
the Ministry of Internal Affairs, the Ministry of Interior and 
of Foreign Affairs and the Ministry of Health of the Russian 
Federation in Moscow on 23 and 24 July to discuss and 
exchange views on the drug situation in the EU and Russia. 
The meeting marked the Director’s first official visit to Russia, 
which was a follow-up to a Russian official visit to the EMCDDA 
in September 2018.
Data protection activities
Regulation (EU) 2018/1725 on data protection was fully 
observed during the year and the activities required regarding 
the data-protection records in particular were carried out. 
Furthermore, the EMCDDA Management Board approved, in 
its meeting in June, a decision on a review of the internal rules 
concerning the processing of personal data in the framework 
of the functioning of the EMCDDA.
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Strategic planning and corporate performance monitoring 
and reporting
The EMCDDA ensured the efficient implementation of the 
annual work programme, which is part of the PD 2019-21. The 
agency reached its operational target to achieve 100 % of the 
results defined in the work programme as level 1 priorities, 
80 % of the level 2 priority results and 50 % of the level 3 
priority results (see Annex 4).
The next PDs — for 2020-22 and 2021-23 (preliminary draft) — 
were also delivered in a timely manner to the EMCDDA’s 
stakeholders and both documents were adopted by the 
Management Board in December 2019.
In terms of corporate reporting, the main output was the 
General Report of Activities 2018, which was adopted by the 
EMCDDA Management Board through written procedure and 
published on 14 June.
The Project Management Programme initiative, which was 
initiated in 2017, was further implemented throughout the year. 
This involved the following projects:
  the roll-out of a project management methodology (Project 
Management Squared — PM2) at the EMCDDA (see ‘ PM2 
at the EMCDDA: in the spotlight’)
  the development and implementation of a management 
information system.
PM2 at the EMCDDA: in the spotlight
To increase its efficiency, the EMCDDA pursued the 
development and adoption of a unified corporate 
project management methodology for its activities. The 
implementation of the methodology, PM2, which is 
widely used by the European Commission, was initiated 
in 2018 and pursued throughout 2019.
Various training sessions for staff members were 
organised, resulting in, by the end of 2019, more than 
50 % of EMCDDA staff having been trained. In total, 
16 staff members passed the exam to obtain PM2 
certification.
PM2 changes the way you prepare and plan a new 
project. The initial brainstorming based on different 
artefacts helps to structure your thinking and include 
many useful aspects, which otherwise could be 
forgotten (Kasia, PM2 certified).
The PM2 governance model helps us to define the 
roles in a project to see where each of us will fit in the 
team to give the best contribution possible to achieve 
efficient solutions (Ricardo, PM2 certified). PM2-certified EMCDDA staff members.
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Financial resources management
The priorities in the field of financial resources management 
were effective and timely planning, monitoring and execution 
of the EMCDDA budget and optimising all of the related 
processes. These were complemented by the efficient use 
of material resources. In this context, the EMCDDA reached 
the maximum level of performance in terms of budget 
execution, with 100 % of commitment appropriations executed 
(see Table 2). In terms of the procurement execution, the 
procurement plan was put in place and successfully executed 
in close collaboration with all units.
The EMCDDA also participated, as an active member, in the 
annual meeting of the Network of Agencies Procurement 
Officers (NAPO).
TAblE 2. Budget execution
Commitment appropriations 100 %
Payment appropriations 98.28 %
Consumption of 2019 (C8) credits 96.48 %
Human resources management
The sound management of existing processes, as required by 
the applicable staff regulations and their implementing rules, 
remained key in 2019.
Another priority was the organisation of appropriate training 
for the agency’s staff to support the effective implementation 
of the EMCDDA’s new long-term strategy. The target of 
providing an average of three training days per staff member 
(KPI 2.3; see Annex 4) was only partially achieved owing to the 
budgetary constraints experienced by the agency in 2019.
In 2019, the staff performance appraisal and promotion 
procedures and tools were adjusted and a new electronic tool 
for appraisals became operational.
Facilities support services
In the area of logistics and infrastructure management, 
ensuring a healthy and safe working environment remained 
key in 2019. To that end, the identification of health and safety 
risks for staff remained one of the main priorities of the agency, 
as did increasing effectiveness, efficiency gains and cost 
savings, including through further synergies with EMSA. The 
information included in the risk registry was adapted following 
the annual risk assessment exercise that was delivered in 
2019.
The agency also implemented further measures to guarantee 
the efficient use of the EMCDDA infrastructure, with special 
attention paid to controlling utilities-related costs and to 
building possible further synergies with EMSA, as well as to 
ensure a safe working environment; in this respect, it is worth 
noting that the agency managed a reduction of its carbon 
footprint from 6.12 to 5.98 tonnes of carbon dioxide per 
person in 2019.
In line with the policy in place at the EMCDDA, this was 
complemented by environmentally friendly measures (an 
internal environmental report was delivered in 2019). The 
agency also continued to contribute to the inter-agency 
Greening Network.
Information and communication technology support 
services
The EMCDDA’s information and communication technology 
(ICT) programmes and services are developed and delivered in 
line with the triennial objectives, which are to implement and 
support core business and corporate projects and processes 
and to provide a continuously stable environment that 
supports existing basic and advanced services.
Concerning providing support for core business areas, in 
2019, the priority was to maintain and develop the EMCDDA’s 
established online data-collection platforms, in particular 
Fonte and the EDND.
Support was also provided to corporate areas, particularly 
planning and performance-monitoring activities, namely for 
the development of the corporate management information 
system, which is now part of the EMCDDA’s new Project 
Management Programme initiative (see ‘Strategic planning 
and corporate performance monitoring and reporting’), as well 
as to human resources and financial management processes.
The optimal allocation and prioritisation of ICT resources was 
supported by the internal ICT steering committee by refining 
priorities and deciding on the intensity of work to be devoted 
to each activity, depending on the most critical organisational 
needs.
Synergies and efficiency gains
Synergies with EMSA were further pursued in the areas of staff 
training, infrastructure management and ICT.
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CHAPTER 1
Management Board’s analysis 
and assessment
The Management Board has analysed and assessed the 
Authorising Officer’s (Director’s) General Report of Activities 
for the financial year 2019.
The Management Board appreciates the performance of the 
Centre in implementing its work programme and welcomes 
in particular the very positive results of the EMCDDA’s fourth 
external evaluation.
In assessing the report, the Management Board wished to 
emphasise the following achievements:
  The EMCDDA presented its annual overview of the 
European drug situation — the EDR — together with 30 
Country Drug Reports. The publication and launch of the 
third joint EMCDDA-Europol EDMR, at a press conference 
and a stakeholders’ event, was another highlight in 2019.
  In terms of support for policy, the EMCDDA continued 
to support drug policy dialogue at EU and national 
levels and was very active in providing support to the 
European Commission and the External Action Service 
on activities with third countries. The Director presented 
the work of the agency to the new LIBE Committee of the 
European Parliament (following the European Parliament 
elections in May 2019). A working arrangement between 
the EMCDDA and Albania was signed in March and the 
Director paid official visits to Montenegro and Russia.
  The EMCDDA maintained close communication with the 
EU Member States, in particular with the Reitox network 
of NFPs, and undertook various technical or institutional 
missions in Member States and welcomed delegations 
of Member States at its premises. The Director paid 
high-level institutional visits to Croatia and Latvia. The 
President of Portugal, Marcelo Rebelo de Sousa, visited 
the EMCDDA on 10 July.
  In 2019, the first year of operation of the new legislative 
framework on NPS, the EMCDDA continued to play 
a leading role in ensuring the continuous and robust 
implementation of the EU EWS on NPS. Two new working 
arrangements were signed with ECHA and EFSA to 
implement the new NPS legislation, in addition to the ones 
already concluded with Europol, the ECDC and the EMA.
  In the area of monitoring new trends in the drug 
phenomenon, the EMCDDA made further progress on 
developing novel data sources, including wastewater-based 
epidemiology and web surveys on drugs and hospital 
emergencies data. The agency started a ‘Futures’ exercise 
to anticipate the developments in the EU drug situation.
  In terms of cooperation with third countries, the agency 
successfully completed the IPA 6 project and started 
a new IPA 7 project in July with a total budget of 
EUR 1 million and a duration of three years. On 1 January, 
the EMCDDA launched the EU4MD project, a new 
technical cooperation project for ENP partner countries 
that is financed by the ENI. EU4MD has a total budget of 
EUR 3 million and is planned to run over three years.
  The Management Board appointed 15 high-level 
scientists as members of the EMCDDA Scientific 
Committee for a three-year mandate (2020-22) through 
a selection procedure that followed a call for expressions 
of interest in the Official Journal of the European 
Union. The contribution of the EMCDDA to the third 
Lisbon Addictions conference as a co-organiser and 
active participant in the event were highly valued by the 
Management Board.
  The agency continued to show operational efficiency, 
with a high level of implementation of the 2019 work 
programme, and reached an outstanding performance in 
terms of budget execution, with 100 % of commitment 
appropriations executed.
In conclusion, the Management Board welcomes the General 
Report of Activities 2019, which provides an excellent 
overview of the agency’s achievements as set out in the work 
programme adopted by the Board.
2
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CHAPTER 2
Management
l Management Board: main decisions
As usual, the Management Board met twice during the year. 
The first meeting took place on 27 and 28 June and the second 
was on 12 and 13 December.
At the June meeting, the Management Board adopted the 
new EMCDDA Financial Regulation, following the positive 
opinion of the European Commission. The Director presented 
the highlights of the EMCDDA’s budgetary and financial 
performance, as well as the main achievements of the 
EMCDDA in 2018 based on the General Report of Activities. 
The Management Board gave a favourable assessment of the 
EMCDDA’s final annual accounts for 2018 and congratulated 
the Director and his staff on the excellent budgetary execution.
On the basis of the recommendation of the Budget Committee 
and the Executive Committee, the Management Board 
adopted amending budget No 1 for the 2019 EMCDDA budget.
The Management Board adopted measures to rationalise 
the expenditure for statutory meetings. While continuing 
simultaneous interpretation at the meetings of the 
Management Board in three active languages (English, French 
and German) and in three rotating passive languages, all 
meetings of the Budget and Executive Committees will be 
held in English from December 2019. The duration of the 
Management Board’s mid-year meeting (June) was reduced 
to one full day from 2020. Finally, a meeting of the Budget 
Committee will be held at the EMCDDA premises in autumn 
(October) only if urgent issues have to be discussed.
In the area of international cooperation, the Management 
Board mandated the Director to negotiate working 
arrangements with Kosovo and Serbia, as well as with any of 
the remaining three Western Balkan countries covered by the 
EMCDDA IPA project (Bosnia and Herzegovina, Montenegro 
and North Macedonia), should any of these countries put 
forward a request. The Board also approved the working 
arrangement between the EMCDDA and the Ministry of Health 
of Ukraine, and mandated the Director to sign it on a date and 
place to be jointly decided between the Ministry of Health of 
Ukraine and the EMCDDA Director. The Management Board 
mandated the Director to negotiate a working arrangement 
with Algeria.
The meeting included an exchange of views about the main 
trends and developments in the drug situation in Europe, 
based on the EDR 2019. After a presentation by the EMCDDA, 
the Chair invited the Netherlands and UK delegations to briefly 
present recent developments in the innovative area of mobile 
health applications.
The European Commission informed the Management Board 
members about its report and staff working document on the 
EMCDDA’s external evaluation, adopted on 14 May, and on the 
follow-up to the report.
The Management Board welcomed the end-term monitoring 
report of the EMCDDA 2016-18 Strategy and work programme 
and congratulated the Centre for the good results achieved.
The Director updated the Management Board on the state 
of implementation of the recommendations issued by the 
IAS of the European Commission from 2015 onwards. The 
Management Board endorsed the EMCDDA’s action plan that 
was created in response to the 2018 IAS audit on publications 
management. The Management Board adopted the EMCDDA 
implementing rules for the new Regulation (EU) 2018/1725 
on data protection. Finally, the Board member for Luxembourg 
provided his colleagues with an update on the developments 
in the cannabis policy in Luxembourg.
At its 60th meeting on 12 and 13 December, the European 
Commission provided an update on the negotiations for the 
EU multiannual financial framework for 2021-27. As usual, at 
the December meeting, the Management Board adopted the 
EMCDDA’s 2020 budget and preliminary draft budget for 2021.
The budget for 2020 gives EUR 16 288 600 as the main 
revenue to be provided by the EU 2020 subsidy to the 
EMCDDA and gives EUR 439 095 as the contribution by 
Norway and EUR 291 644 as the contribution by Turkey for 
their participation in the work of the EMCDDA.
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The year 2021 will be the first year of the period to be covered 
by the new EU multiannual financial framework for 2021-27, 
the definition and adoption of which are still in progress. The 
preliminary draft budget for 2021 gives EUR 18 106 000 as 
the main revenue to be provided by the EU 2021 subsidy to 
the EMCDDA and gives EUR 515 668 as the contribution by 
Norway and EUR 324 184 as the contribution by Turkey for 
their participation in the work of the EMCDDA.
In line with the provisions of Article 32 of the Framework 
Financial Regulation applicable to EU agencies and of 
the EMCDDA Financial Regulation, the Management 
Board adopted the EMCDDA’s PD for the period 2020-22, 
including the 2020 work programme, of which the European 
Commission and the EMCDDA Scientific Committee had 
given a favourable opinion. The Board also adopted the 
EMCDDA’s preliminary draft PD for 2021-23, which includes 
the preliminary draft work programme for 2021.
The Management Board adopted the EMCDDA action plan to 
follow up on the recommendations of the EMCDDA’s external 
evaluation, carried out during 2018. Actions were planned 
taking into account the current EMCDDA mandate.
The Management Board elected Ms Sanja Mikulič (a human 
resources professional) as a Budget Committee member for 
a second mandate, from 1 January 2020 to 31 December 
2022.
The Management Board approved the working arrangement 
between the EMCDDA and the Office for Combating Drugs, 
the Ministry of Internal Affairs and the Ministry of Health of the 
Government of the Republic of Serbia, following the favourable 
opinion of the European Commission, and mandated the 
Director to sign the working arrangement on a date and place 
to be jointly decided by the parties.
The Director informed the Board members, both in June and in 
December, about the EU4MD project funded by the European 
Commission, which covers ENP partner countries and will 
allow ongoing, emerging and future trends in the drug market, 
as well as their implications for security and health, to be 
identified, analysed and reported on effectively. The project 
started on 1 January. The total estimated EU financing for this 
project should amount to about EUR 3 million for the whole 
period, and the first part of the revenue was entered into the 
EMCDDA draft budget for 2019 (about EUR 1 million).
The Director provided the Board with information on the state 
of implementation of the Reitox development framework, as 
well as on the measures taken to improve the implementation 
of the co-financing of the Reitox network of NFPs.
In a restricted session, the European Commission informed the 
Management Board about the procedure for the renewal of the 
mandate of the Director. The Management Board appointed 
the members of the new Scientific Committee and established 
a reserve list for 2020-22, according to the Rules of Procedure 
of the EMCDDA Management Board. The Management Board 
further approved the list of experts to be used for 2020-22 by 
the EMCDDA Director to extend, as deemed necessary, the 
Scientific Committee for the purposes of the risk assessment 
of NPS.
After the presentation of the main findings of the joint 
EMCDDA-Europol 2019 EDMR, the Management Board 
discussed the latest developments in cocaine for a better 
informed debate. The Chair invited some delegations to briefly 
share recent national developments and challenges in the 
production, trafficking and use of cocaine.
The Director updated the Management Board on the state 
of play concerning the outstanding recommendations of the 
IAS of the European Commission. The Management Board 
endorsed the IAS strategic internal audit plan for the EMCDDA 
for 2020-22.
Portugal presented some conclusions about the third Lisbon 
Addictions conference, which took place in Lisbon from 23 to 
25 October and was organised by the Portuguese SICAD, the 
journal Addiction (of the Society for the Study of Addiction), 
the EMCDDA and the International Society of Addiction 
Journal Editors (ISAJE).
Turkey provided information about the EU-funded project 
entitled ‘Strengthening the data-collection capacity of TUBIM’, 
the Turkish Monitoring Centre for Drugs and Drugs Addiction, 
in which the twinning component is being implemented 
together with Romania.
Finally, Mr Denis Huber, Executive Secretary of the Pompidou 
Group of the Council of Europe, informed the Management 
Board members about the process of the statutory revision of 
the Pompidou Group.
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l Executive Committee: main decisions
In 2019, the Executive Committee met four times in Lisbon 
(5 April, 27 June, 18 October and 11 December).
On 5 April, the Executive Committee congratulated the 
EMCDDA on the provisional accounts for 2018 and, in 
particular, the high execution rate and best outturn result ever. 
The Executive Committee agreed on a proposal of measures 
to rationalise the expenditure for statutory meetings, to be 
submitted to the Management Board members for adoption in 
June.
At its meetings of 5 April and 27 June, the Executive 
Committee reviewed the items of the draft agenda of the 
Management Board meeting of 27 and 28 June. The European 
Commission suggested in April that a thematic discussion 
could take place on the main trends in the drug situation, 
based on the findings of the EDR 2019, at the Management 
Board meeting in June.
At its meeting of 27 June, the Executive Committee adopted, 
on behalf of the Management Board, general provisions for 
giving effect to the Staff Regulations on the employment 
of contract staff. The Executive Committee welcomed the 
decision of the Director to put in place measures to ensure 
the most efficient use of the appropriations earmarked for 
the EMCDDA co-financing of NFPs and proposed some 
modifications to the document, to be submitted to the 
Management Board members for information in December.
On 18 October, the Executive Committee prepared for the 
Management Board meeting of 12 and 13 December. The 
Chair of the Budget Committee provided feedback on the 
informal Budget Committee meeting, which took place in 
Brussels on 11 October. It was decided that the Chair of the 
Management Board and the Chair of the Budget Committee 
would write a letter to the Management Board members to ask 
for their support to secure adequate funding for the agency for 
2020 and over the next years (multiannual financial framework 
for 2021-27), by contacting their national authorities. The letter 
would be accompanied by an annex with key figures on the 
budgetary situation.
In its meeting of 11 December, the Executive Committee 
passed the items of the draft agenda of the Management 
Board meeting of 12 and 13 December.
The Executive Committee assessed the recommendation 
from the pre-selection panel for nominations to the Scientific 
Committee and the reserve list and agreed to submit these 
to the Management Board. The Executive Committee also 
validated the list of candidates who were considered suitable 
for inclusion in the list of experts to be used by the EMCDDA 
Director to extend the Scientific Committee for the purposes 
of the risk assessment of NPS and agreed to submit it to the 
Management Board.
The Executive Committee adopted, on behalf of the 
Management Board, general provisions for giving effect to 
the Staff Regulations on the non-application of the European 
Commission decision on (1) the maximum duration for the 
recourse to non-permanent staff in the European Commission 
services (opt-out), (2) implementing rules laying down 
guidelines on whistleblowing and (3) implementing rules for 
dealing with professional incompetence (only for officials).
At the beginning of each meeting of the Executive 
Committee, the Chair of the Budget Committee reported on 
the conclusions of the meetings held prior to the Executive 
Committee meetings and on the recommendations made by 
the Budget Committee.
l Budgetary and financial management
l  Information in the report on budgetary and financial management (Article 93 of the Framework Financial Regulation)
Information on budgetary and financial management is 
covered by the report included in the EMCDDA’s Annual 
accounts 2019.
In terms of procurement execution, the procurement plan was 
put in place, in line with the EMCDDA 2019 management plan, 
and successfully executed in close collaboration with all units.
The negotiated procedures launched during the course of the 
year are outlined in Tables 3 and 4.
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TAblE 3. EMCDDA negotiated procedures in 2019
Tendering 2019 figures Number of direct contracts
Number of 
framework 
contracts
Negotiated procedures — see Annex I, 11.1(a), of ‘Financial regulation applicable 
to the general budget of the union’ (exceptional procedures)
1 1 0
Negotiated procedure — single tender (*) 85 85 0
Negotiated procedure — at least three candidates 5 5 0
Negotiated procedure — at least five candidates 2 1 1
Open procedures 1 0 1
European Commission frameworks joined 8 0 8
(*) Including appointment letters and very low-value contracts.
TAblE 4. EMCDDA negotiated procedures' values in 2019
Works Supplies Services Total for 2019
Number of 
contracts
Volume of 
contracts 
(EUR)
Number of 
contracts
Volume of 
contracts 
(EUR)
Number of 
contracts
Volume of 
contracts 
(EUR)
Number of 
contracts %
Volume of 
contracts 
(EUR)
%
EuR > 1 000 
and ≤ 15 000
7 11 159 3 9 391 75 339 823 85 92 % 360 373 60 %
EuR > 15 000 
and ≤ 60 000
0 0 0 0 5 163 398 5 5 % 163 398 27 %
EuR > 60 000 
and ≤ 144 000
0 0 0 0 2 132 000 2 2 % 132 000 13 %
Total 7 11 159 3 9 391 82 635 221 92 100 % 655 771 100 %
l  Summary of budgetary operations, revenue and expenditure
The information about the appropriations transferred in 
2019 can be found in the report on budgetary and financial 
management, as included in the EMCDDA’s Annual accounts 
2019. The EMCDDA Management Board approved two 
amending budgets in 2019, which were duly published.
The results achieved under the main financial/performance 
indicators for 2019 are 100.00 % execution of commitment 
appropriations, 98.28 % implementation of payment 
appropriations, and 96.48 % execution of appropriations 
carried forward from 2018 and 0.08 % for cancelled/unused 
payment appropriations.
l  Information on grants, contribution and service level agreements
Pursuant to the decision taken by the relevant EU authorities, 
in 2019 the EMCDDA concluded two grant agreements with 
the European Commission for the following purpose:
  The execution of the ‘EU4Monitoring Drugs project’. This 
is a project for technical assistance aimed at enhancing 
the capacity of ENP countries (extending to include 
on an ad hoc basis the ‘neighbours of the neighbours’) 
to monitor drug markets and contribute to improving 
national and regional responses to security and health-
related threats posed by contemporary drug markets and 
related issues. This includes, via the improved monitoring 
of drug markets, the identification of new threats, the 
co-production of practical recommendations to respond 
better to existing and emerging drug problems, and 
a wider dissemination of findings to support policies, 
practice and a more informed debate on drug problems 
in the countries concerned. The project concerns the 
following beneficiary countries: Algeria, Egypt, Israel, 
Jordan, Lebanon, Libya, Morocco Palestine, Tunisia (for 
the Southern Neighbourhood Partnership) and Armenia, 
Azerbaijan, Belarus, Georgia, Moldova and Ukraine (for 
the Eastern Neighbourhood Partnership). The execution 
of the project started on 1 January 2019 and will cover 
a period of 36 months/3 years (that may be extended for 
one additional year). The appropriations allocated from 
the EU budget for the execution of the whole project 
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amount to in total EUR 3 000 000 (to be earmarked as 
assigned appropriations in the EMCDDA budget). They 
will be provided to the EMCDDA by annual instalments, in 
accordance with the agreement concluded between the 
EMCDDA and the Commission for this purpose. The first 
instalment (concerning 2019) amounted to EUR 1 197 
414 and was entered into the EMCDDA 2019 budget as 
assigned appropriations.
  The execution of a further project for technical assistance 
to the beneficiary countries of the EU IPA (IPA II). This 
project (‘EMCDDA-IPA 7 project’) aims at further 
integrating the IPA beneficiaries (Albania, Bosnia and 
Herzegovina, Kosovo, Montenegro, North Macedonia and 
Serbia) into the activities of the EMCDDA and the Reitox 
network. The execution of the project started on 1 July 
2019 and will cover a period of 36 months. A total of 
EUR 1 000 000 was allocated from the EU budget for the 
execution of the whole project and was entered into the 
EMCDDA 2019 budget as assigned appropriations.
Concerning service level agreements (SLAs) concluded by the 
EMCDDA, the following SLAs were in force in 2019:
  SLA between the EMCDDA and the European 
Commission (DG for Human Resources and Security) 
for the provision of services (upon agreed compensation 
whose amount depends on the actual services provided) 
relating to staff’s training, health, safety and security;
  SLA between the EMCDDA and the European 
Commission (Paymaster Office) for the provision of 
services (upon agreed compensation whose amount 
depends on the actual services provided) relating to the 
management of staff’s pecuniary rights;
  SLA between the EMCDDA and the European Commission 
(DG for Budget) for the provision of services (upon agreed 
compensation whose amount depends on the actual 
services provided) relating to the use of the electronic 
management and accounting system (ABAC) system;
  SLA between the EMCDDA and the European 
Commission (DG for Informatics) for the provision of 
services (upon agreed compensation whose amount 
depends on the actual services provided) relating to the 
hosting of the ABAC, ICT procurements, e-procurement 
(e-Prior services) and secure connectivity/access to 
Commission-hosted applications (RACHEL);
  SLA between the EMCDDA and the European 
Commission (DG for Informatics) for the provision of 
services by the EU Computer Response Team — CERT-
EU — relating to ICT security (computer emergency 
response);
  SLA between the EMCDDA and EMSA relating to the 
shared management of the premises of their headquarters 
and the sharing of the associated services and costs;
  SLA between the EMCDDA and EMSA relating to 
synergies for the sharing of ICT services and equipment.
l Human resources management
l Human resources developments
The work to align the EMCDDA’s human resources processes 
and policies with the reform of the EU Staff Regulations 
continued in 2019. This included, in particular, the adoption 
of implementing rules on procedures for dealing with 
professional incompetence (which only apply to EMCDDA 
officials) (Decision C(2019) 6855), on the non-application at 
the EMCDDA of the European Commission Decision on the 
maximum duration for the recourse to non-permanent staff in 
the Commission services (DEC/MB/19/14), on guidelines on 
whistleblowing (DEC/MB/19/15) and on general provisions for 
implementing Article 79(2) of the Conditions of Employment 
of Other Servants of the European Union, governing the 
conditions of employment of contract staff employed under 
the terms of Article 3a thereof (DEC/MB/19/02).
As in previous years, the EMCDDA played an active role in 
discussions held by several inter-agency working groups in this 
area.
As regards the EMCDDA 2019 establishment plan, the 
total number of posts was equal to that in the EMCDDA 
establishment plan for 2018 (i.e. 76 posts), pursuant to the 
relevant decision of the EU budget authority.
l  Brief description of the results of the screening/benchmarking exercise
The results of the EMCDDA 2019 staff screening exercise 
reflect the EMCDDA’s efforts to ensure the effective and 
efficient allocation and use of its resources. The results show 
that 71.07 % of the EMCDDA’s human resources capacity was 
devoted to operational activities in 2019 and only 19.11 % 
was allocated to administrative support and coordination; 
the remaining 9.82 % was assigned to operations considered 
neutral (see Annex 2).
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l Assessment by management
The EMCDDA has set its internal procedures for budget 
execution and internal control, while defining and 
implementing a partially decentralised management model, 
in accordance with the EMCDDA Financial Regulation, which 
integrally transposes the text of European Commission 
Delegated Regulation (EU) No 2019/715 on the Framework 
Financial Regulation for EU agencies.
As a consequence, both the operational and the financial 
decisions required for the implementation of the EMCDDA’s 
PD and budget have been delegated to the heads of unit. 
The administration unit provides support to managers 
for budgetary and financial management execution and 
implementation of financial transactions, as well as for internal 
budget planning, monitoring and reporting.
These procedures have been codified and all of the EMCDDA’s 
deputy authorising officers have received specific training and 
information on their roles, duties and liabilities, in accordance 
with the provisions of Financial and Staff Regulations.
The key actors in and steps of the EMCDDA procedures for 
budget execution can be summarised as follows (see also 
Tables 5 and 6):
  Project manager: initiates and provides operational input 
for the administrative and financial operations related to 
project implementation (e.g. technical specifications for 
procurement procedures, cost estimates and ‘certified 
correct’ for payments).
  Budget and financial management team: undertakes 
budget planning and monitoring, checking for consistency 
with the PD and budget allocations. Financial and 
contractual support officers provide assistance in the 
preparation of administrative and contract documents 
with the input of the project manager involved.
  Financial management: initiating officers carry out 
operations using the EMCDDA’s ABAC, prior to decisions 
of the authorising officer.
  Executive office unit: the verifying officer carries out ex 
ante financial checks.
  Head of unit or Scientific Director: gives authorisation 
for budgetary and legal operations and acts as deputy 
authorising officer by delegation (by the Director as the 
EMCDDA authorising officer) for the execution of the 
tasks/activities of his/her unit, within the limits of the 
adopted EMCDDA annual work programme and budget.
  Accounting officer: executes and records payments and 
recovery orders.
The procedures presented above are consistent with the 
EMCDDA’s project-based working methods, which aim to 
integrate activity and resource management, in accordance 
with activity-based management/activity-based budgeting 
principles. In this context, the EMCDDA established 
procedures for planning, monitoring and reporting, with 
a clear indication of the actors involved, their roles and their 
responsibilities.
After the adoption of the new ‘Operating framework for the 
Reitox system’ in January 2003, a new grant agreement model 
was introduced for the annual co-financing of activities by the 
Reitox NFPs. This agreement requires that an external audit 
is carried out each year by an independent body or expert, 
in order to certify that any financial documents submitted 
to the EMCDDA comply with the financial provisions of the 
agreement, that the costs declared are the actual costs and 
that all receipts have been declared.
TAblE 5. Key features of the EMCDDA’s partially decentralised management mode
Level of operations (and actors) Role/operations
Decentralised level (operational 
and technical units)
Operational initiative/input and operational and financial decisions by delegation in order to implement the 
work programme and budget
Central level (executive office 
unit and administration unit)
Coordination and management of executive planning, monitoring, reporting and assessment of the 
implementation of the work programme and budget. Administrative and financial support, management and 
control of implementation
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TAblE 6. Key actors involved in the implementation of the EMCDDA’s partially decentralised management model
Level of operations Actors Role/operations
Decentralised level 
(operational and technical 
units)
Project manager and head of the 
unit concerned
Initiates and provides operational input to the operations required to 
implement projects
Central level (administration 
unit)
budget planning and monitoring 
team
Checks the consistency of operations with the adopted work programme 
and budget. budgetary appropriations to be committed are set aside
Human resources management 
team
Defines rights and checks compliance with Staff Regulations for staff-
related management and expenditure
Financial management team
Prepares the required administrative and legal supporting documents 
and controls compliance with applicable regulations, and processes the 
required financial operations
Central level (executive 
office unit)
Verifying officer Ex ante verification
Decentralised level 
(operational and technical 
units)
Head of unit/deputy authorising 
officer
Authorises budgetary and legal commitments and payments
Central level (administration 
unit)
Accounting officer Executes and records payments and recovery orders
The EMCDDA’s activities and operations are scrutinised by 
several processes and actors:
  external audits by the European Court of Auditors (twice 
a year);
  external audits for specific projects (IPA-funded projects, 
etc.);
  discharges by the European Parliament (once a year);
  internal audits by the IAS of the European Commission 
(once a year);
  opinions of the European Commission’s services on the 
agency’s PD (once a year);
  external periodical evaluations (set as every six years in 
the EMCDDA Founding Regulation);
  agreements by the European Commission on 
implementing rules for Staff Regulations (one agreement 
for each rule);
  consent by the European Commission on the possible 
deviation of the EMCDDA Financial Regulation from the 
European Commission’s Framework Financial Regulation 
for decentralised agencies;
  the European Data Protection Supervisor for compliance 
with Regulation 45/2001 (by prior notification and upon 
complaint);
  the European Anti-Fraud Office (upon complaint);
  the Ombudsman (upon complaint);
  the European Court of Justice (upon complaint).
Ex ante controls of financial transactions were applied 
exhaustively throughout 2019 to verify their compliance with 
the EMCDDA Financial Regulation and the corresponding 
implementing rules. These controls were carried out swiftly to 
ensure that payment deadlines were met, legal commitments 
were concluded in a timely manner and income was recovered 
promptly, without prejudice to the application of corrections, if 
required.
Financial workflows were properly defined and a sound system 
of authorisation of access to the ABAC was put in place. The 
manual of procedures was applied and updated, as required.
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l  Assessment of audit results during 2019 and the follow-up of audit plans, audits and recommendations
In 2019, following up on observations and recommendations 
expressed by the European Court of Auditors, the EU Budget 
Authority and the IAS, the EMCDDA implemented measures to 
further improve its management and internal control systems, 
as outlined below.
l Internal Audit Service
The implementation of the two recommendations arising 
from the 2015 IAS audit on ICT project management, and still 
outstanding at the end of 2018, was accomplished by mid-
2019. These recommendations — relating to the definition 
and adoption of a requirements management process and 
to the definition and adoption of a systems development 
methodology — were therefore submitted to the IAS for review 
in early July 2019. The internal auditor has subsequently 
asked for additional evidence of implementation for these two 
recommendations, which was promptly made available. As 
of the end of 2019, such recommendations had not yet been 
formally closed by the IAS.
Concerning the 2017 IAS audit on the management of 
data collection, validation and quality assurance in the 
EMCDDA, the two recommendations issued were sent to 
the IAS for review. These concerned (1) the performance of 
a comprehensive business needs analysis aimed at identifying 
current and emerging needs and related ICT functionalities 
to support data collection, validation and quality assurance 
processes and (2) the review and improvement of the 
EMCDDA data quality management framework. The first of 
these recommendations — rated as ‘very important’ — was 
formally closed by the IAS in early 2020. As regards the second 
recommendation — rated as ‘important’ — the IAS requested 
evidence regarding certain structural elements to be included 
in the EMCDDA data quality management framework. This 
particular recommendation will therefore remain open until 
such elements are provided to the internal auditor.
Following its audit on publications management in the EMCDDA, 
the IAS issued its final report on 29 March, which contained three 
recommendations, rated by the internal auditor as ‘important’. 
These three recommendations are summarised below:
Recommendation No 1: The EMCDDA should develop and 
adopt a framework for a systematic collection and assessment 
of stakeholders’ feedback concerning its publications. The 
framework should define (1) the methods and tools to be 
applied, (2) the decision-making process when assessing 
feedback and how lessons learnt are to be incorporated 
into the EMCDDA publications and (3) the audit trail of the 
underlying controls.
Recommendation No 2: The EMCDDA should (1) establish 
comprehensive rules on the assessment of product feasibility 
and of decision-making arrangements for ‘ad hoc’ publications, 
(2) instruct staff on publication planning processes apart 
from the publication project planning form and (3) provide 
in the annual management plans more detailed information 
concerning the relevance, volume and workload of scientific 
articles produced by staff.
Recommendation No 3: The EMCDDA should (1) where 
cost-effective, adapt the main workflows, managed by both the 
scientific and the communication units, to the specific needs 
of different types of publications, and (2) incorporate those 
workflows into the Guide to producing EMCDDA scientific 
publications (and formally adopt this guide).
The action plan aimed at dealing with these IAS 
recommendations was prepared in a timely manner, submitted 
to the IAS and subsequently endorsed by the EMCDDA 
Management Board in its June 2019 meeting.
In late October 2018, the IAS conducted a fact-finding mission 
on potential internal control weaknesses in the agency, an 
initiative triggered by some issues related to human resources 
management that were reported to the IAS by the European 
Anti-Fraud Office (OLAF). The results of that mission, first 
delivered at the end of 2018, did not lead to any findings that 
would even remotely relate to fraud. A number of issues and 
recommendations have, nevertheless, been raised by the IAS; 
a summary of these is provided below:
  With a view to promoting transparency and enhancing 
controls in recruitment procedures, the EMCDDA should 
consider revising its current guidelines, in order to provide 
further clarification on the meaning of potential conflicts 
of interest.
  Internal controls in the area of staff selection/recruitment, 
aimed at ensuring full alignment with applicable rules, 
should be reinforced. Moreover, the ICT application used 
in calculating the eligibility of minimum work experience 
requirements should be updated.
  With a view to mitigating risks of non-compliance with 
the regulations in force, the EMCDDA should request 
technical advice from the European Commission on how 
to revise the method for the calculation and allocation 
of ‘priority points’ in the framework of promotion/
reclassification procedures.
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The issues and recommendations mentioned above were 
confirmed by the final letter of the IAS of late January 2019. 
The EMCDDA promptly declared its willingness to endorse 
these IAS recommendations.
The IAS conducted, in May 2019, a comprehensive risk 
assessment at the EMCDDA, which led to its 2020-22 
strategic internal audit plan. Two prospective topics — on 
human resources management and on strategic planning and 
programming — were identified for this three-year period; in 
addition, a reserve audit topic on international cooperation 
was scheduled in the strategic plan. This strategic internal 
audit plan was approved by the EMCDDA Director and was 
subsequently endorsed by the agency’s Management Board in 
its meeting of December 2019.
l European Court of Auditors
The EMCDDA followed up on the recommendations expressed 
by the European Court of Auditors in its 2018 annual report 
(Annual report on EU agencies for the financial year 2018), as 
outlined as follows:
(3.25.8.) The contracts for the engagement of interim workers 
have been concluded and implemented in accordance with 
the applicable EU and Portuguese legislations, the latter 
transposing in Portugal the provisions of Directive 2008/104/
EC. In this context, the interim workers concerned have been 
assigned tasks that entail a level of responsibility, duties and 
obligations that are lower than the ones required by and/or 
applying to the members of the EMCDDA’s statutory staff. In 
particular, these workers are not bound to and/or are excluded 
from the responsibilities and obligations that apply to the 
EMCDDA’s statutory staff, pursuant to the applicable EU 
Staff and Financial Regulations. The remuneration of these 
interim workers, as stated in the contracts concluded for 
their engagement, reflects this situation. In the EMCDDA’s 
view, this is in line with the principle of equal treatment set by 
Directive 2008/104/EC, which applies to persons doing ‘the 
same job’. In this context the actual net remuneration of the 
interim workers concerned corresponds to about 87 % of the 
referred lowest basic salary of EMCDDA staff and to 147 % 
of the minimum national salary, according to the Portuguese 
legislation. The contract between the EMCDDA and the 
temporary work agency explicitly refers to the obligation 
of the latter to comply with all aspects of the applicable 
legislation (the Portuguese legislation that transposes 
Directive 2008/104/EC). In this context, the temporary work 
agency is the entity legally responsible for this compliance 
and exposed to the risk of litigation concerning the execution 
of the contracts concluded with the interim workers for their 
assignment to the EMCDDA.
Without prejudice to the above and to the residual use of 
interim workers, the EMCDDA has assessed and clarified 
the tasks that may be carried out on a temporary basis by 
means of the services of these workers, in order to further 
ensure the consistency of these tasks with the corresponding 
remuneration levels and minimise and prevent any risk relating 
to the compliance with the relevant legal framework. This does 
not put into question the fact that the agency contracted to 
provide services for temporary work is, and will remain, the 
main entity responsible for this compliance
(3.25.9.) No linear correlation exists between the 2007-18 
increase of the EU subsidy and of Norway’s contribution. 
Indeed, the increase of the latter stems exclusively from the 
application of the formula defined in the relevant Agreement, 
whilst the increase of the former has been determined 
by the annual decision of the EU’s budget authority. The 
aforementioned Agreement defines, in broader terms, 
a different formula/method for the adjustment of the minimum 
contribution to be made by Norway. The application of this 
formula/method requires some interpretation, for which the 
EMCDDA does not have the required legal capacity, as it is not 
a signing Party of the Agreement.
The EMCDDA has addressed the Parties concerned to clarify 
and confirm the method to be used for this adjustment.
(3.25.10.) The EMCDDA duly invited the number of tenderers 
required by the applicable financial rules to ensure the 
necessary competition, in accordance with the low value of 
the contracts at stake. The decision of the invited tenderers 
to participate or not, was exclusively determined by their free 
choice, which may have been motivated by different legitimate 
reasons, including the lack of attractiveness/interest of the 
contract due to its reduced scope and low value.
The EMCDDA has pursued its ongoing efforts to facilitate, as 
much as possible, the participation to its procurements for 
low-value contracts, without prejudice to the principles of 
proportionality and equal treatment of all potential tenderers.
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l  Follow-up on observations from the discharge authority
l  Measures taken in light of the observations and comments that accompanied the decision on discharge for 2017
Observation No 8 of the European Parliament discharge 
decision
Welcomes the suggestion of the Court to publish vacancy 
notices also on the website of the European Personnel 
Selection Office (EPSO) in order to increase publicity; notes 
that, according to the Centre’s reply, it is committed to 
assessing the cost-benefit of this action and, in addition, plans 
to publish all future vacancies in the inter-agency job board 
developed by the EU Agencies Network.
Measures taken by the EMCDDA
The EMCDDA has duly taken the necessary follow-up 
measures. In particular, it has carried out the above-mentioned 
assessment. On this basis, and pursuant to EPSO’s decision 
to simplify the conditions required for the publication at stake 
(and therefore substantially reduce the relevant costs), the 
EMCDDA has decided to systematically publish its future 
vacancy/selection notices on EPSO’s website, in addition to 
publishing them on the EMCDDA website and on the inter-
agency job board developed by the EU Agencies Network.
Observation No 10 of the European Parliament discharge 
decision
Notes that, according to the Court’s report, by the end 
of 2017, the Centre was not yet using any of the tools 
launched by the Commission aimed at introducing a single 
solution for the electronic exchange of information with 
third parties participating in public procurement procedures 
(e-procurement); notes that, according to the Centre’s reply, 
the Centre has set up the tools required for ‘e-invoicing’ and 
has planned the preparatory operations required to be able 
to use ‘e-tendering’ and ‘e-submission’ from October 2018 as 
required by the relevant legal framework; calls on the Centre to 
report to the discharge authority on the progress made.
Measures taken by the EMCDDA
The EMCDDA has duly taken the necessary follow-up measures, 
via the entering into operation/use of the ‘e-tendering’ and 
‘e-submission’ modules from October 2018, as required by 
the EU legal framework governing ‘e-procurement’ and the 
timetable for its roll-out. This completed the measures already 
taken to set up and use the ICT tool for ‘e-invoicing’.
Observation No 11 of the European Parliament discharge 
decision
Notes that, according to the Court’s report, there is a need 
to strengthen the accounting officer’s independence by 
making him directly responsible to the Centre’s Director and 
Management Board; notes that, according to the Centre’s 
reply, in its view the current organisational setting has not 
affected the independence of the accounting officers; notes, 
furthermore, that the Centre is, however, ready to follow up on 
the recommendation of the Court.
Measures taken by the EMCDDA
The EMCDDA has duly taken the necessary follow-up 
measures, by establishing that the EMCDDA accounting 
officers directly report, in administrative terms, to the EMCDDA 
Director, who becomes their direct hierarchical superior 
and reporting officer, without prejudice to their functional 
independence, reporting and accountability to the EMCDDA 
Management Board, in accordance with the applicable 
financial rules.
Observation No 12 of the European Parliament discharge 
decision
Notes that the Commission’s IAS outlined the importance 
of undertaking an analysis of the needs of data-collection, 
validation and quality assurance processes and to review 
its data quality management framework and its alignment 
with the Centre’s Strategy 2025; observes that the Centre 
adopted an action plan to address these recommendations in 
December 2017; calls on the Centre to report to the discharge 
authority on the developments made in this regard.
Measures taken by the EMCDDA
All substantial measures envisaged in the action plan 
regarding the two recommendations emerging from the 2017 
IAS audit on the management of data collection, validation and 
quality assurance in the EMCDDA have been implemented, 
and communicated to the IAS for formal closure.
Observation No 13 of the European Parliament discharge 
decision
Notes with regret that one of the recommendations, graded 
as ‘important’, included in the 2013 IAS audit on budget and 
monitoring is still not fully implemented; notes with concern 
that, according to the Court’s report, several recommendations 
included in the 2015 IAS audit on ICT project management are 
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only partly implemented and still ongoing; calls on the Centre 
to report to the discharge authority on the implementation of 
these recommendations.
Measures taken by the EMCDDA
The last recommendation from the IAS’s 2013 audit on 
budget and monitoring was fully implemented in 2018 and 
this was communicated to the IAS for formal closure (this 
recommendation concerned the need for continuous, coherent 
and reliable information on the achievement of planned results 
at the EMCDDA, with a view to rendering the activity-based 
budgeting system fully effective as a management tool).
All recommendations from the IAS’s 2015 audit on ICT project 
management in the EMCDDA have been implemented and 
this was communicated to the IAS for formal closure. Five of 
these recommendations have already been formally closed 
(recommendations concerning the sound alignment between 
business needs and the ICT long-term strategy and tools, the 
adoption of an ICT project methodology and the automation 
of project management processes) and two are in the process 
of formal closure (recommendations concerning the definition 
and adoption of a requirements management process and of 
a systems development methodology).
3
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CHAPTER 3
External evaluations
Further to the fourth external evaluation of the EMCDDA, 
which was carried out by the European Commission in 2018, 
the European Commission published a report on 14 May, 
positively evaluating the work of the agency. The report 
confirms that, over the period 2013-18, the agency continued 
to be widely recognised as a true hub of scientific excellence 
in Europe and internationally, providing factual, objective, 
reliable and comparable data at the European level on drugs, 
drug addiction and their consequences.
The evaluation report and an accompanying staff working 
document providing more detailed information are available 
online.
Subsequently, a follow-up action plan was adopted by the 
EMCDDA Management Board in December. The document 
was drafted by the EMCDDA in a period of budgetary 
uncertainty and the actions envisaged may be overambitious 
should the appropriate resources not be made available to the 
agency. Furthermore, actions were planned taking into account 
the current EMCDDA mandate.
4
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CHAPTER 4
Risk management, compliance with 
and effectiveness of the internal control 
standards
As in previous years, a comprehensive risk identification and 
assessment exercise aimed at improving risk management at 
the EMCDDA was carried out in 2019. The central risk register 
was regularly updated. This register identifies, for each area, 
the estimated risk level, impact and response, the mitigating 
measures currently in place and the list of programmes, 
projects and actions that will contribute to the reduction of the 
outstanding residual risk levels. As mentioned in Chapter 2, 
‘Assessment of audit results’, risk assessment was carried 
out continuously at the EMCDDA throughout the year, while 
a comprehensive analysis was performed by the managers in 
the context of the preparation of the PDs.
A comprehensive document that reviews and sets out the 
progress made in the implementation of the EMCDDA’s 
internal control standards was drawn up in early 2013. This 
document has been regularly updated since then, up to (and 
including) 2019.
Following a Management Board decision taken in December 
2017, a new Internal Control Framework (ICF) applicable to 
the EMCDDA was adopted. This new ICF is fully consistent 
with the European Commission standards, internal control 
principles and relevant guidelines. A document with a full 
repository of the state of play of implementation of the 17 
ICF principles was drafted throughout 2018 and it was near 
completion in December 2018. (The final steps required an 
analysis of a number of important pieces of information, such 
as the preliminary results of the IAS fact-finding mission on 
internal control weaknesses, the conclusions emerging from 
the external evaluation and the results obtained under the 
survey of EMCDDA staff engagement; all of these arrived in 
either late November or mid-December 2018.) The year 2018 
was therefore a transition year as regards the monitoring of 
the agency’s compliance with internal control standards and 
principles. The first version of the repository on the new ICF 
was approved by the EMCDDA Director in late March 2019; 
this document will be updated where necessary.
The EMCDDA’s business continuity plan had already reached 
maturity in 2018, after completing the set-up of the back-up 
facilities in Madrid for the purposes of disaster recovery. For 
this reason, the residual risks relating to business continuity 
have been considered low since 2018.
Progress has also been made regarding the implementation 
of measures aimed at improving project management in the 
EMCDDA, particularly in the ICT sector. As a result, the two 
remaining recommendations issued by the IAS 2015 audit 
report on ICT project management (which had still not been 
implemented by the end of 2018) reached the final phase of 
implementation by mid-2019 and therefore were sent to the 
IAS for review.
In addition, clear progress was made on mitigating certain 
governance and technical ICT-related risks, which led to their 
removal from the EMCDDA central risk register.
The monitoring of performance, supported by KPIs, was further 
consolidated throughout 2019, building on the achievements 
of previous years. This was the fifth year in which KPIs were 
in place for all of the main areas of work in the annual work 
programme; the agency has continued developing the 
necessary data-collection and reporting mechanisms, has 
piloted some new measurement tools, has refined working 
definitions and has developed an internal monitoring and 
evaluation plan.
The performance model has continued evolving to reflect 
the current strategic direction and organisational needs set 
out in the EMCDDA Strategy 2025, as well as developments 
concerning the performance models implemented by other EU 
agencies.
As a result, the agency’s performance model has been 
changing, from a model that used to include a high number of 
KPIs (i.e. 50 KPIs in 2018) to a model with a limited number 
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of composite KPIs (i.e. 10 KPIs), that is, KPIs built on and 
measured by sets of underlying lower level performance 
indicators. This new performance model was first presented in 
the EMCDDA PD 2019-21.
Moreover, the agency has been consistently working on 
the development of an ICT tool to integrate the planning 
and monitoring of activities (MATRIX). The customisation of 
MATRIX started in 2018. The results of the initial piloting phase 
led management to make a positive decision on the adoption 
of MATRIX as a corporate management information system 
for operational planning, monitoring and reporting of activities. 
Following the adoption of a business implementation plan, the 
roll-out of MATRIX has been initiated and the implementation 
of a substantive training programme for all staff started at the 
end of 2019.
Internal EMCDDA coordination mechanisms (e.g. the heads of 
unit meetings, editorial board meetings, product coordinating 
meetings, ICT steering committee meetings and scientific 
coordination meetings) further contributed to strengthening 
risk management processes, by enhancing the capacity of 
managers and other key staff to closely monitor all major 
issues related to the timely and effective implementation of 
planned activities, the delivery of outputs and the achievement 
of results.
The following factors are worth mentioning as regards the 
materialisation of risks to the performance of the EMCDDA’s 
activities and consequently to the agency’s capability to reach 
its core objectives.
The nominal value of the EU subsidy to the EMCDDA for 
2019 was EUR 263 400 lower than for 2013. This decrease 
represented a high-level risk to the agency, in view of the 
serious erosion of its value in real terms, as well as of the 
increased financial needs of the agency. The increase, again in 
2019, of the weighting factor applicable to staff remunerations 
and the looming end (in 2020) of building rental discounts will 
probably render this risk even more serious.
Risks related to the implementation of operational activities 
materialised once again in 2019. This concerns, in particular, 
the lack of proper funding for certain Reitox NFPs, which has 
been apparent since 2014, with a peak in 2016 and 2017. In 
particular, funding cuts made by national authorities to some 
NFPs’ budgets in the last quarter of 2016 (cuts that were 
maintained in 2017) may imply future reductions in co-funding 
provided by the EMCDDA. This situation improved somewhat 
in 2018, as certain Member States maintained or increased 
their financial contributions to their NFPs. Nevertheless, the 
current situation could trigger further negative consequences 
for the capabilities of the NFPs with regard to complying with 
their reporting obligations. In addition, these difficulties have 
been compounded by lingering budget constraints faced 
by the EMCDDA itself, which have led to decreases in the 
amounts it grants to NFPs.
Therefore, rationalisation of the NFP reporting package needed 
to be carried out in past years and has been maintained 
in 2019; this has involved, notably, regular reviews of the 
availability of core data needs, on the basis of properly defined 
priorities; providing feedback to the NFPs on their performance 
in respect of the availability of core data and their reporting 
obligations towards the EMCDDA; and enhancement of 
coordination and performance monitoring.
Furthermore, reductions in the reporting capacities of Member 
States have been evident since 2015. The initial consequence 
of this is that the timeliness and comprehensiveness of Member 
States’ reporting on new threats and drug developments have 
been affected; moreover, some comparative data became 
unavailable, which curtailed the possibility of carrying out useful 
analyses at the European level. Following materialisation of this 
risk, it became clear that closer monitoring of Member States 
and the provision of more feedback to the Member States on 
their reporting performance was envisaged and is currently 
ongoing. In addition, an assessment of the implementation of 
the key epidemiological indicators in the Members States takes 
place every three years and the NFPs are provided with the 
necessary feedback. Additionally, the evaluation of the reporting 
capacity of Member States could be included in forthcoming 
systemic reviews. Furthermore, the Certification of the Reitox 
national focal point project, includes the use of a comprehensive 
tool that allows the NFPs to assess the implementation of their 
core tasks, which comprises quality control measures at national 
level (for details, see ‘Main area Business drivers: partnership’). 
Finally, but equally as important, closer attention ought to 
be paid to reporting biases and statistical approaches; these 
measures should allow corrective action to be taken by those 
Member States chiefly affected.
l  Implementation of the EMCDDA Anti-fraud Strategy
In 2011, the European Commission adopted its new Anti-fraud 
Strategy aimed at improving the prevention, the detection and 
the conditions for investigations of fraud and the achievement 
of adequate reparation and deterrence. The action plan 
accompanying this document tasked OLAF with the provision 
of a methodology and guidance to help EU decentralised 
agencies develop their own anti-fraud strategies (or update 
an existing one) by taking into account the principle of ‘zero 
tolerance’ for fraud and the specific context of agencies, which 
are usually small entities.
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In July 2012, the European Parliament, the Council and the 
European Commission agreed on a Joint Statement which 
included a Common Approach presenting 66 conclusions/
statements that reflected a common and legally non-
binding approach concerning a series of issues relating to 
EU decentralised agencies. Conclusion/statement no 66 
recommended EU agencies to be more active and to better 
communicate in relation to fraud prevention.
With regard to the above, OLAF has drawn up the required 
methodology and guidance for EU agencies and has organised 
workshops to support the latter for the conception and 
implementation of their anti-fraud strategies. Some EMCDDA 
staff members were able to attend one of these workshops in 
June 2015.
As indicated by OLAF itself, the use of the methodology defined 
is not compulsory but it should allow each agency to draw up 
a tailored anti-fraud strategy adapted to its specific context and 
risk profile and proportionate to the latter, having due regard to 
the cost and benefit of the measures to be implemented.
The approved EMCDDA Anti-fraud Strategy reflects OLAF’s 
methodology and guidance. It completes and develops the 
measures already taken by the EMCDDA on this matter, in 
particular the rules on internal investigations by OLAF, the 
initiatives for awareness-raising on staff ethics, the rules on 
gifts and hospitality offered by third parties, and the guidelines 
on serious wrongdoing and whistleblowing.
In this context, the EMCDDA strategy takes into account 
the priorities set by the European Commission within the 
framework of the Common Approach on EU decentralised 
agencies, especially the proper handling of conflicts 
of interest and the development of anti-fraud activities 
through prevention, detection, awareness-raising and closer 
cooperation with OLAF.
The EMCDDA Anti-fraud Strategy was adopted by Management 
Board decision on 23 June 2016 (DEC/MB/16/09) and has 
been fully implemented. The current Head of the Executive 
office was appointed as the EMCDDA OLAF coordinator by 
Director’s Decision on 24 August 2016.
5
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l Declaration of assurance by the Authorising Officer
I, the undersigned, Director of the European Monitoring Centre for Drugs and Drug Addiction in 
my capacity as Authorising Officer:
  declare that the information contained in this report gives a true and fair view (6);
  state that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance with 
the principles of sound financial management, and that the control procedures put in place 
give the necessary guarantees concerning the legality and regularity of the underlying 
transactions;
  state that this reasonable assurance is based on my own judgement and on the information 
at my disposal, such as the results of the self-assessment, the observations of the Internal 
Audit Service, the implementation of recommendations issued under ex post assessments 
and the lessons learnt from the reports of the Court of Auditors for years prior to the year of 
this declaration;
  confirm that I am not aware of anything not reported here that could harm the interests of 
the institution.
Done in Lisbon on 13 May 2020
Alexis Goosdeel 
Director
(6) ‘True and fair’ in this context means a reliable, complete and correct view on the state of affairs in the service.
Annexes
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l  Annex 1 Organisational chart
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l  Annex 2 Staff details
l Breakdown of EMCDDA staff as of 31 December 2019
Categories/grade Officials
Gender Temporary 
agent
Gender
Male Female Male Female
Administrators
15
14 1 1
13 1 1 3 2 1
12 3 3 5 4 1
11 7 3 4
10 1 1 3 1 2
9 1 1 8 3 5
8 9 2 7
7 4 2 2
6 2 2
5
Subtotal of administrators 6 6 0 42 20 22
Assistants
11 1 1
10
9 3 2 1
8 1 1 2 2
7 3 1 2
6 1 1 8 4 4
5 3 1 2
4 1 1
3 1 1
2
1
Subtotal of assistants 3 0 3 21 11 10
TOTAL 9 6 3 63 31 32
EMCDDA staff Function group
Gender
Male Female
Contract agents
IV 8 3 5
III 8 3 5
II 15 1 14
I 3 3
TOTAL of contract agents 34 10 24
Total EMCDDA 
staff
Gender
Male Female
106 47 59
Percentage 44 % 56 %
Seconded national 
expert
1
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I Staff by nationality
0 5 10 15 20 25 30 35
Ocials (9) Temporary agents (63) Contract agents (34)
United Kingdom
Sweden
Finland
Slovakia
Slovenia
Romania
Portugal
Poland
Austria
Netherlands
Malta
Hungary
Luxembourg
Lithuania
Latvia
Cyprus
Italy
Croatia
France
Spain
Greece
Ireland
Estonia
Germany
Denmark
Czechia
Bulgaria
Belgium
l  Number of days of leave authorised under the flexitime and compensatory leave schemes
Function group 
and grade
Number 
of days
AD5 12
AD6 0
AD7 37.5
AD8 44.5
AD9 47.5
AD10 12.5
AD11 39
AD12 5.5
AD13 0
AD14 0
AD15 0
AD16 0
AST1 0
AST2 0
AST3 0
AST4 1
AST5 27.5
AST6 42
AST7 15.5
AST8 27
Function group 
and grade
Number 
of days
AST9 0
AST10 0
AST11 0
gFI1 0
gFI2 0
gFI3 10.5
gFII4 4
gFII5 8
gFII6 19.5
gFII7 32.5
gFIII8 0
gFIII9 28.5
gFIII10 4.5
gFIII11 14.5
gFIII12 3
gFIV13 6
gFIV14 10.5
gFIV15 1.5
gFIV16 15
gFIV17
Total 469.5
l Results of the 2019 benchmarking exercise 
Job type (sub-)category Percentage of staff
Administrative support and coordination 19.11%
Administrative support 18.45%
Coordination 0.67%
Operational 71.07%
Top-level operational coordination 4.33%
Programme management and 
implementation
54.59%
Evaluation and impact assessment 0.00%
general operational 12.15%
Neutral 9.82%
Finance/control 9.82%
linguistics 0.00%
Total 100.00%
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l  Annex 3 Implementation of the 2019 work programme by objectives and expected outputs/results
This annex presents, in detail, the activities contained within the work programme for 2019 and how they were carried out during 
the course of the year. It is available online.
l  Annex 4 Key performance indicators
This annex is available online.
l  Annex 5 Key external events, conferences and meetings
This annex is available online.
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l  Annex 6 Members of the EMCDDA’s statutory bodies
l Management Board
The Management Board consists of one representative from each Member State, two representatives of the European Commission, 
two independent experts who are particularly knowledgeable in the field of drugs, designated by the European Parliament, and 
one representative from each country that has concluded an agreement with the EMCDDA (i.e. Norway and Turkey). Non-voting 
observers, such as those from international organisations with which the agency cooperates, may also be invited to Management 
Board meetings.
Country/organisation Member Substitute
Belgium Claude gIllARD Vladimir MARTENS
Bulgaria Tsveta Nikolaeva RAYCHEVA Zahari Nikolov ZARKOV
Czechia Jamila VEDRAlOVÁ lucia KISSOVA
Denmark lars PETERSEN Sofie DENCKER
Germany Daniela luDWIg Stephan bRANDT
Estonia Anna-liisa PÄÄSuKENE Ain PEIl
Ireland Jim WAlSH Eamon KEENAN
Greece Christos KOuIMTSIDIS gerasimos PAPANASTASATOS
Spain María Azucena MARTÍ PAlACIOS Elena AlAVAREZ MARTÍN
France laura d’ARRIgO (Chair) Nicolas PRISSE
Croatia Željko PETKOVIĆ Sanja MIKulIĆ
Italy Maria CONTENTO Elisabetta SIMEONI
Cyprus Stelios SERgIDES Maria AFXENTIOu
Latvia Dzintars MOZgIS
Lithuania Inga JuOZAPAVIČIENÉ gražina bElIAN
Luxembourg Xavier POOS Alain ORIgER
Hungary Mónika SZÁSZIK Ibolya CSÁKÓ
Malta Richard MuSCAT Marilyn ClARK
Netherlands Victor SANNES
Austria Franz PIETSCH (Vice-Chair) Raphael bAYER
Poland Piotr JAbŁOŃSKI bogusława buKOWSKA
Portugal João gOulÃO Manuel CARDOSO
Romania Constantin NEgOIŢĂ Critian DuŢĂ
Slovenia Vesna-Kerstin PETRIČ Jože HREN
Slovakia Nadežda lObODÁŠOVÁ Eva DEbNÁROVÁ
Finland Elina KOTOVIRTA Kari PAASO
Sweden Johan CARlSON David lORENTZON
United Kingdom Rosanna O’CONNOR lauren COMbER
European Commission Paraskevi MICHOu and Olivier ONIDI
laurent MuSCHEl and Floriana SIPAlA or 
Wojciech KAŁAMARZ
European Parliament Meni MAllIORI and Tomas ZAbRANSKY Wolfgang gÖTZ
Norwegian representatives lilly Sofie OTTESEN Hege Christina bREDESEN
Turkish representatives İbrahim H. SEYDIOĞullARI Murat SARIgÜZEl
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l Observers
Scientific Committee Anne line bRETTEVIllE-JENSEN
Reitox spokesperson lies gREMEAuX
uNODC gilberto gERRA
Council of Europe Pompidou group Denis HubER
WHO Carina FERREIRA bORgES
l Executive Committee
The Management Board is assisted by an Executive Committee. The Executive Committee is made up 
of the Chair and the Vice-Chair of the Management Board, two other members of the Management 
Board representing the Member States and appointed by the Management Board, and two 
representatives of the European Commission. The Executive Committee prepares and follows up the 
decisions of the Management Board and assists and advises the EMCDDA Director.
laura d’ARRIgO France (Chair of the Management board)
Franz PIETSCH Austria (Vice-Chair of the Management board)
Xavier POOS luxembourg
João gOulÃO Portugal
Claude gIllARD belgium (Chair of the budget Committee, observer)
Two representatives of the European Commission
l Scientific Committee
The members of this committee are selected for their independence and proven expertise in 
a particular field/speciality, as indicated below.
Field/speciality Scientific Committee Member(s)
basic biological, neurobiological and behavioural 
research
Fernando RODRIguEZ de FONSECA
Rainer SPANAgEl
Drug policy
Henri bERgERON
Anne line bRETTEVIllE-JENSEN
Krzysztof KRAJEWSKI
Population-based research
Catherine COMISKEY
Paul DARgAN
Dirk J. KORF
Matthew HICKMAN
Supply, supply reduction letizia PAOlI
Demand reduction
gerhard bÜHRINgER
Marina DAVOlI
Fabrizio FAggIANO
gabriele FISCHER
Henk gARRETSEN
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l  Annex 7 Use of the available resources
Notes: All amounts in this annex are given in euros. This annex lists the agency’s overheads (i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that 
indirectly aim to implement the EMCDDA mission/task/work programme, as their immediate aim is to support operational activities and staff). They are distributed among operational activities 
in proportion to the human resources assigned for the implementation of these activities.
l Main areas
Work 
programme 
action areas
Main actors 
for implemen-
tation/cost 
objects 
(see Annex 1)
Assigned human resources (full-time equivalent/year) Initial allocation of budget resources — non-assigned appropriation
Final allocation of budget resources — 
non-assigned appropriation
Executed budget — non-assigned 
appropriation
Officials Temporary agents
Contract 
agents
Seconded 
national 
experts
Total 
human 
resources
Direct cost 
of operations
Indirect 
costs of 
operations
Total 
budget
Direct 
cost of 
operations
Indirect 
costs of 
operations
Total 
budget
Direct 
cost of 
operations
Indirect 
costs of 
operations
Total 
budget 
execution
Main area 1: 
health
HEA, SAS, SDI, 
RTX&EP, COM, ICT, 
DIR/EXO
2.55 23.1 11.75 0 37.4 3 552 090 1 638 599 5 190 689 3 775 393 1 416 097 5 191 490 3 775 311 1 416 066 5 191 376
Main area 2: 
security
SAS, SDI, HEA, 
RTX&EP, COM, ICT, 
DIR/EXO
0.5 8.9 2.95 1 13.35 2 108 070 972 464 3 080 534 2 240 594 840 415 3 081 009 2 240 545 840 397 3 080 942
Main area 
3: business 
drivers
DIR/EXO, SDI, 
COM, RTX&EP, 
ADM, ICT, HEA, 
SAS
5.95 32 14.3 0 52.25 5 267 262 2 429 817 7 697 079 5 598 390 2 099 877 7 698 267 5 598 268 2 099 831 7 698 099
Total 9 64 29 1 103 10 927 422 5 040 880 15 968 302 11 614 377 4 356 389 15 970 766 11 614 124 4 356 294 15 970 418
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l Statement of financial performance
Economic outturn account 2019 2018 Variation
Contributions of European Free Trade Association countries belonging to the 
European Economic Area
412 372.68 412 932.41 -559.73
Recovery of expenses 18 983.47 34 399.08 -15 415.61
Revenues from administrative operations 291 102.31 276 550.49 14 551.82
Other operating revenue 16 115 578.36 15 591 436.84 524 141.52
Total operating revenue 16 838 036.82 16 315 318.82 522 718.00
Administrative expenses -13 220 176.69 -12 892 148.92 -328 027.77
All staff expenses -10 934 223.41 -10 343 817.11 -590 406.30
Fixed asset related expenses -305 135.65  -274 773.02 -30 362.63
Other administrative expenses -1 980 817.63 -2 273 558.79 292 741.16
Operational expenses -4 409 442.54 -4 187 441.16 -222 001.38
Other operational expenses -4 409 442.54 -4 187 441.16 -222 001.38
Total operating expenses -17 629 619.23 -17 079 590.08 -550 029.15
Surplus/(deficit) from operating activities -791 582.41 -764 271.26 -27 311.15
Financial revenues 2 806.88 0.66 2 806.22
Financial expenses -1 392.27 -4 713.78 3 321.51
Surplus/(deficit) from non-operating activities 1 414.61 -4 713.12 6 127.73
Surplus/(deficit) from ordinary activities -790 167.80 -768 984.38 -21 183.42
Economic outturn for the year -790 167.80 -768 984.38 -21 183.42
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l EMCDDA 2019 budget execution by nature of expenditure
Commitment appropriations
Title Description EUR
1
Expenditure relating to persons working with the EMCDDA
Staff in active employment 10 756 057.90
Other staff-related expenditure (exchange of officials, etc.) 0.00
Total under Title 1 10 756 057.90
2
Expenditure for support activities
Investment in immovable property, rental of buildings and associated costs 864 598.36
Data processing 467 351.29
Movable property and associated costs 57 078.00
Current administrative expenditure + postal charges and telecommunications 65 709.98
Socio-medical infrastructure 15 400.04
Total under Title 2 1 470 137.67
3
Expenditure for operational activities
Statutory meetings 146 823.74
Expenditure on formal and other meetings + representatives’ expenses 357 135.67
Studies, surveys, consultations 451 941.78
Publishing and translations 495 354.11
Reitox — European network on drugs and drug addiction 2 060 602.63
Missions 238 384.69
Total under Title 3 — Section 1.01 3 750 242.62
Section 1.02 — Total core budget 15 976 438.19
Section 1.03
4
Expenditure relating to other subsidies
Eu financing of specific projects
4a. IPA 6: financing for implementing pre-accession strategy 106 635.78
4b. IPA 7: financing for implementing pre-accession strategy 147 405.33
4c. Eu4MD 927 737.15
5 Other expenses (reserve) 0.00
Total budget 17 152 196.22
Notes: The amounts encompass (1) budget appropriations for the current year (C1) and (2) appropriations resulting from internal assigned revenue incurred in 2019 (C4).
The amounts committed under Titles 4a, 4b and 4c contain commitment appropriations and, where this was the case, are carried forward from the previous year.
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l Execution of budget: credit consumption, 2019
Commitment appropriations
Title Description Fund source (*) % consumption of available credits
1 Staff C1 100.00
2 Expenditure for support activities C1 100.00
3 Expenditure for operational activities C1 99.99
4a Expenditure relating to IPA 6 R0 97.53
4b Expenditure relating to IPA 7 R0 14.74
4c Eu4MD R0 77.48
Total consumption of core budget (Titles 1, 2 and 3) 100.00
Note: (*) C1 refers to EMCDDA main budget (Eu subsidy: European Commission Dg HOME + Norway and Turkey's contributions); R0 refers to external assigned revenue pro-
jects (namely IPA 6, IPA 7 and Eu4MD) all granted by Dg NEAR of the European Commission.
l Balance sheet: assets
Assets 31 December 2019 31 December 2018 Variation
A. Non-current assets
Intangible assets 495 124.77 435 941.94 59 182.83
Property, plant and equipment 69 942.19 97 460.74 -27 518.55
Computer hardware 215 361.63 317 295.55 -101 933.92
Furniture and vehicles 29 965.83 37 816.26 -7 850.43
Long-term pre-financing 0.00 114 022.25 -114 022.25
Total non-current assets 810 394.42 1 002 536.74 -192 142.32
B. Current assets
Short-term pre-financing 121 363.75 469 486.13 -348 122.38
Short-term receivables 364 100.70 436 020.23 -71 919.53
Current receivables 137 513.87 199 743.89 -62 230.02
Other (sub-total) 210 586.83 236 276.34 -25 689.51
Accrued income 0.00 0.00 0.00
Deferred charges 210 586.83 236 276.34 -25 689.51
Short-term receivables with consolidated entities 16 000.00 0.00 16 000.00
Cash and cash equivalents 2 048 742.85 723 896.86 1 324 845.99
Total current assets 2 534 207.30 1 629 403.22 904 804.08
Total 3 344 601.72 2 631 939.96 712 661.76
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l Balance sheet: liabilities
Liabilities 31 December 2019 31 December 2018 Variation
Liabilities
Net assets 858 779.62 1 648 947.42 -790 167.80
Accumulated surplus/deficit 1 648 947.42 2 417 931.80 -768 984.38
Economic outturn for the year — profit+/loss- -790 167.80 -768 984.38 -21 183.42
Total net assets 858 779.62 1 648 947.42 -790 167.80
Current liabilities
Current liabilities — accounts payable 2 485 822.10 982 992.54 1 502 829.56
Current payables 218 817.77 64 943.81 153 873.96
Other 824 496.09 823 051.45 1 444.64
Accrued charges 823 626.97 821 223.98 2 402.99
Deferred income 869.12 1 827.47 -958.35
Accounts payable with consolidated Eu entities 1 442 508.24 94 997.28 1 347 510.96
Pre-financing received from consolidated Eu entities 1 442 508.24 94 997.28 1 347 510.96
Total current liabilities 2 485 822.10 982 992.54 1 502 829.56
Total 3 344 601.72 2 631 939.96 712 661.76
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l Budget outturn account for the financial year 2019
Budget outturn account 2019 2018
Revenue
balancing European Commission subsidy + 15 286 600.00 15 445 600.00
Other subsidy from European Commission (IPA 6) + 2 197 414.00
Fee income +
Other income (Norway contribution + Turkey contributuon + C4 internal assigned revenues + bank 
interests amending budget Nos 1 and 2)
+ 711 635.04 723 882.64
Total revenue (a) 18 195 649.04 16 169 482.64
Expenditure
Title 1: Staff
Payments - 11 072 683.72 10 445 666.13
Appropriations carried over - 738 035.39 58 870.35
Title 2: Administrative expenses
Payments - 1 228 585.47 1 102 888.05
Appropriations carried over - 259 311.52 300 736.67
Title 3: Operating expenditure
Payments - 4 224 260.02 4 461 067.47
Appropriations carried over - 779 961.46 95 545.65
Total expenditure (b) 18 302 837.58 16 464 774.32
Outturn for the financial year (a-b) -107 188.54 -295 291.68
Cancellation of unused payment appropriations carried over from previous year (C8 Titles 1 and 2) + 12 561.07 27 093.70
Adjustment for carry-over from the previous year of appropriations available at 31 December arising 
from assigned revenue
+ 109 337.88 322 278.86
Exchange differences for the year (gain +/loss -) +/- 99.01 -1 911.27
IPA 6 final balance to be reimbursed to the European Commission Dg NEAR at 31 December 2019 2 702.10 -28 768.80
Norway pro rata 2019 -540.86 -722.89
Turkey pro rata 2019 -319.26 -426.63
Cancellation of amounts non-reusables 3 987.43
Balance of the outturn account for the financial year 20 638.83 22 251.29
balance year N-1 +/- 22 251.29 189 763.80
Positive balance from year N-1 reimbursed in year N to the European Commission - -22 251.29 -189 763.80
Result used for determining amounts in general accounting 20 638.83 22 251.29
Commission subsidy — agency registers accrued revenue and European Commission accrued expense 15 265 961.17 15 423 348.71
Pre-financing remaining open to be reimbursed by agency to the European Commission in year N+1 20 638.83 22 251.29
Note: Not included in the budget outturn — interest generated by 31 December year N on the European Commission balancing subsidy funds and to be reimbursed to the 
European Commission (liability) (+).
Legal notice: Neither the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) nor any person acting on 
behalf of the agency is responsible for the use that might be made of the information contained in this report.
lisbon: EMCDDA, 2020
Photos: Foreword and Introduction — © EMCDDA, Nuno Saraiva. Cover — © istockphoto.com. Remaining photos — copyright 
information as indicated in captions.
© European Monitoring Centre for Drugs and Drug Addiction, 2020
Reproduction is authorised provided the source is acknowledged.
For any use or reproduction of photos or other material that is not under the EMCDDA's copyright,  
permission must be sought directly from the copyright holders.
doi:10.2810/311765 l ISbN 978-92-9497-450-1 l ISSN: 1725-4558 l Catalogue number: TD-Ab-20-001-EN-N
This publication is only available in electronic format. 
EMCDDA, Praça Europa 1, Cais do Sodré, 1249-289 lisbon, Portugal
Tel. (351) 211 21 02 00 l info@emcdda.europa.eu l 
emcdda.europa.eu l twitter.com/emcdda l facebook.com/emcdda l linkedin.com/company/emcdda l 
instagram.com/emcdda l youtube.com/emcddatube
About this report
The General Report of Activities is an annual 
publication providing a detailed progress report of 
the EMCDDA’s activities over a 12-month period. It 
catalogues the Centre’s achievements in each area 
of its annual work programme. The report is a useful 
information source for all those seeking comprehensive 
information on the Centre and its work.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction is the hub of drug-related information in 
Europe. Its mission is to provide the European Union 
and its Member States with ‘factual, objective, reliable 
and comparable information’ on drugs and drug 
addiction and their consequences. Established in 1993, 
it opened its doors in Lisbon in 1995, and is one of the 
European Union’s decentralised agencies. The Centre 
offers policymakers the evidence base they need for 
drawing up drug laws and strategies. It also helps 
professionals and researchers pinpoint best practice 
and new areas for analysis.
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